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Abstract 
 
Glaucoma is a progressive disease that results in the degeneration of retinal 
ganglion cells and their axons, which make up the optic nerve. From the comparative 
analysis of degeneration patterns in the retina and of the axons directly exiting the retina, 
it has been proposed that damage to the axons in the optic nerve head occurs before the 
loss of retinal ganglion cells. Therefore, the focus of this dissertation was to identify 
biology in the optic nerve head that might contribute to the development of glaucoma.  
The phagocytic activity of astrocytes was discovered by studying the effects of 
disease and injury on the cells in the optic nerve using genetic and acute mouse models. 
These astrocytes were initially identified by the expression of Lgals3, a phagocytosis-
related gene more commonly found in phagocytes. Astrocytes had specific Lgals3 
expression in the myelination transition zone that increased in mouse models of 
glaucoma. Further analysis of myelination transition zone astrocytes using electron 
microscopy revealed the presence of axonal debris, myelin remnants, and lipid droplets 
inside the astrocyte cytoplasm. Primary astrocyte cultures demonstrated that continuous 
and repeated phagocytosis of myelin induced lipid droplet formation. 
These studies describe a dynamic role of astrocytes in optic nerve biology. Optic 
nerve astrocytes actively phagocytose myelin and, in disease, do so to the point that the 
myelin accumulates within the cell and lipid droplets form. Further investigations of 
myelin stability and astrocyte phagocytosis may lead to new clues in the progression of 
axon damage, while understanding lipid droplet biology in the optic nerve might lead to 
the identification of biomarkers in glaucoma. 
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Chapter 1: Introduction 
 
Introduction to glaucoma 
Glaucoma is an optic neuropathy that is one of the leading causes of blindness in 
the world [1]. It is an irreversible disease that interferes with the processing and 
transmission of images from the retina to the brain due to the death of retinal ganglion 
cells (RGCs). Glaucoma primarily affects the elderly population and risk factors include 
elevated intraocular pressure (IOP) and excavation of the optic disk.  
Elevated IOP is typically due to the decreased outflow of the aqueous humor. 
When the angle between the iris and cornea is narrowed or closed, this is diagnosed as 
primary angle closure glaucoma (PACG). The angle remains open in primary open angle 
glaucoma (POAG) and microscopic blockage in the trabecular meshwork reduces the 
outflow pathway. Secondary glaucoma may result from anterior synechia, which is when 
the iris presses anteriorly against the cornea or trabecular meshwork. Glaucoma can also 
occur in eyes with normal pressure. IOP modulation through pharmacological agents or 
surgery is currently the only method that has shown to be effective in the treatment of 
glaucoma, even though the mechanism is not well understood [2].  
Excavation of the optic disk is also known as cupping. The optic cup is the central 
region of the optic disk and there is an increase in the ratio of the optic cup to the optic 
disk that can be observed in glaucoma. The region between the cup and disk is the 
neuroretinal rim. The neuroretinal rim also decreases with optic disk cupping. Altogether 
these signs can indicate damage to the lamina cribrosa and optic nerve [3-5], but the 
appearance of the optic disk is variable and is insufficient to diagnose on that parameter 
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alone. Cupping is thought to occur due to elevated IOP deforming the lamina cribrosa, 
which is a collagenous structure that axons pass through before forming the optic nerve. 
However, optic disk cupping also occurs without elevated IOP.  
There are two important observations that have framed the direction of glaucoma 
research. The first observation is that RGC loss in the retina occurs in a particular arcuate 
pattern [6; 7]. In animal models, RGC loss is seen as a sectorial pattern [8-12]. The 
regions of RGC loss are well-defined and, in humans, the arcuate pattern of RGC death 
typically does not cross the horizontal meridian. The reason for these observations is that 
there is a spatial relationship between RGCs somas and their axon bundles in the optic 
nerve head (ONH) [13-15]. Axon bundles at the superior or inferior poles of the optic 
disk correspond to RGCs that are superior or inferior, respectively, to the horizontal 
meridian. Therefore an injury which affects the axons in the ONH is likely the cause of 
the pattern of RGC death observed in glaucoma.  
The optic nerve head 
The ONH is the region of interest in this thesis because of the likelihood that the 
injury that initiates glaucoma occurs here. The most anterior portion of the ONH is the 
pre-laminar region, which contains bundles of axons that have emerged from the retinal 
nerve fiber layer (NFL) and are exiting the optic disk. Posterior to the pre-laminar region 
is the laminar region which contains the lamina cribrosa. Mice do not have a collagenous 
lamina cribrosa [3; 12; 15; 16] and this region has been referred to as the glial lamina to 
make that distinction [12; 15]. In humans and other mammals including mice, the axons 
in the pre-laminar and laminar region are unmyelinated [3].  
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Myelination of the optic nerve begins distally and proceeds proximally, in 
contrast to other nerves in the central nervous system (CNS) where myelination begins 
near the cell body and myelinates in a distal direction [17]. In humans, myelination 
reaches up to the retrolaminar optic nerve, which begins at the posterior edge of the 
lamina cribrosa. In mice, there is a more gradual transition region and myelination 
completely ends further posteriorly to the sclera than in humans [16]. This region has 
been referred to as the retina-optic nerve junction [18; 19] and we have referred to this 
region as the myelination transition zone (MTZ) [11]. In this thesis, the region from the 
pre-lamina to the posterior edge of the retrolaminar region is included when referring to 
the ONH.  
Mouse models of glaucoma 
Animal models are essential to understanding the molecular mechanisms of 
glaucoma or any other disease. Primates, dogs, cats, pigs, and rodents have all been used 
to study glaucoma [20]. Animal models allow researchers to address specific questions to 
learn more about glaucoma, but researchers must be vigilant in extending the results to 
humans due inherent biological differences between humans and animals. The anatomy 
of the rodent eye, optic nerve, and aqueous humor dynamics are similar to human [21; 
22], except that rodents have less developed lamina cribrosas which lack collagen beams 
[3; 12; 15; 16; 23]. Primate eye anatomy is most similar to humans, especially in the 
structure of the lamina cribrosa. Surgical manipulations can be easier to perform on 
primates due to their relatively large size, but the ethical and financial cost to support a 
large primate colony limits how many biological replicates are feasible to perform. 
Rodents are much more amenable to experimentation because they can be kept in higher 
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population numbers and cost less to maintain. The methods to genetically manipulate 
mice and rats have also been well-developed. This thesis relies on the DBA/2J (D2) 
mouse strain as a model for glaucoma. As such, the D2 model is described in more detail 
and alternative mouse models are briefly discussed.  
DBA/2J glaucoma model 
The work to establish D2 as a glaucoma model has largely been pioneered by 
Simon W. M. John and colleagues [24-26]. D2 is an inbred mouse strain that 
spontaneously develops signs similar to iridocorneal endothelial syndrome and pigment 
dispersion syndrome in humans [24]. These signs develop with age and have varying 
degrees of penetrance, despite the genetically identical nature of the strain. The genetics 
of D2 simplify the model in some ways, but the variability of a disease phenotype 
demonstrates that there are influences yet to be uncovered. These influences may be 
insightful in the application of D2 findings in a human population.   
D2: Iris defects 
Slit lamp examination of 3-6 month (mo) old D2 revealed transillumination 
defects from the deterioration of the iris stroma and iris pigmented epithelial cells [24; 
27]. The free-floating iris pigments may become trapped in the trabecular meshwork and 
block the pores that drain the aqueous humor. Iris displacement can also result in 
synechia that prevents the flow of aqueous humor through the chambers and out the 
trabecular meshwork. Pigment dispersion or synechia can lead to elevated IOP in D2, 
which is similar to pigmentary glaucoma or closed angle glaucoma, respectively [24]. 
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D2: Genetics 
In order to identify the genetics behind iris stromal atrophy (ISA) and iris pigment 
dispersion (IPD), D2 mice were crossed with C57Bl/6J mice and examined for signs of 
glaucoma [25]. Mice displaying iris abnormalities were analyzed using microsatellite 
markers and segregating coat colors. All the mice with iris defects were homozygous for 
two loci inherited from D2 and had brown coat colors instead of the typical black coat of 
C57Bl/6J mice. The loci were isolated from each other using genetic crosses and the 
inheritance of recessive genes in either loci produced a phenotype that was reflective of 
ISA or IPD. 
The ISA locus contained the gene tyrosinase-related protein 1 (Tyrp1) [25; 26]. 
The Tyrp1b allele in D2 contained two amino acid substitutions as compared with the 
C57Bl/6J allele. This gene is involved in the production of melanin and produces a brown 
pigment. Tyrp1b alleles are also responsible for the brown coat color in D2 mice. Defects 
in Tyrp1 was proposed to allow toxic intermediates of melanin production to form and 
cause damage to the melanocytes [28]. Interestingly, the Tyrp1b allele is only toxic when 
the pigment forming pathway is activated. Tyrp1b in albino BALB/cByJ does not cause 
ISA [25]. ISA was induced with the addition of a functional Tyrp1 gene in the same 
BALB/cByJ background strain. Tyrp1b has a direct role in the formation of ISA in D2. 
The gene identified in the ipd locus was glycosylated protein nmb (Gpnmb) [29]. 
The D2 allele, GpnmbR150X, encoded a premature stop codon. GpnmbR150X, like Tyrp1b, 
also appeared to induce toxicity through pigment production. A naturally occurring D2 
strain with hypopigmentation called pearl (D2-pe) was used to show that reduced 
pigment production can negate the effects of GpnmbR150X or Tyrp1b expression. Signs of 
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glaucoma did not manifest in D2-pe unless at least one copy of pe was corrected to 
wildtype. Lower pigment production prevented the manifestation of glaucoma signs in 
mice with GpnmbR150X and Tyrp1b mutations.  
D2.B6-Tyrp1B6GpnmbB6/Sj (D2.Tyrp1B6GpnmbB6) mice were generated to better 
understand the contribution of these two genes to glaucomatous pathology [30]. The mice 
also provide the benefit of being a control strain to D2. The wildtype alleles were 
obtained from C57Bl/6J mice. There is predicted to be no more than 3.3% of C57Bl/6J 
DNA in D2.Tyrp1B6GpnmbB6. Mice up to 12-mos-old did not have the appearance of iris 
disease, IOP elevation, or ocular degeneration [30]. Mice that were 16 to 21-mos old did 
develop some signs of degeneration, but the frequency was low and might be attributed to 
old age.  
A second strain generated as a control to D2 was D2-Gpnmb+/Sj (D2-Gpnmb+). 
This Gpnmb+ allele was present in ancestral D2 mouse strains before the GpnmbR150X 
mutation occurred [26]. The only known difference between D2 and D2-Gpnmb+ is the 
base in Gpnmb+ that reverts the premature stop codon back to an arginine. D2-Gpnmb+ 
have mild signs of ISA but do not generally develop the signs of glaucoma [30]. As in 
D2.Tyrp1B6GpnmbB6, there were a few instances that disease was observed. This may be 
attributed to the Tyrp1b allele or other age-related biology. The ability to use age-matched 
mice that are genetically controlled to D2 expands the usefulness of D2 as a model. 
Control strains decrease the variabilities that might arise from comparing mice of 
difference ages or with different genetics. The studies performed in this thesis 
infrequently used young D2 mice in comparison with aged D2, and primarily utilized 
age-matched D2-Gpnmb+.  
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D2: Glaucomatous degeneration 
Elevated IOP occurred at approximately 6 to 9 mos of age [24; 27]. Female mice 
tended to have iris defects and elevated IOP earlier than males, but the two groups were 
not significantly different in terms of histology. The severity of degeneration within a 
cohort of similarly aged mice can be grouped into stages from no or early signs of 
degeneration (NOE) to severe [8; 27]. These groupings apply to both retinas and optic 
nerves. 
Progressive thinning of the NFL, RGC layer, and inner nuclear layer (INL), as 
well as cupping of the optic disk were seen in sagittal sections [24; 27]. By 10 mos of 
age, 34% of D2 had severe loss while 55% of the cohort displayed NOE [27]. In 17 to 19-
mo-old D2, the percentage with severe RGC loss increased to 80%. Wholemount retinas 
demonstrated that the pattern of degeneration in D2 started tended to start focally and 
then expanded to wedge-shaped regions [8-12]. This pattern of RGC loss was analogous 
to the pattern observed in human glaucoma [6; 7] and also implicated damage to the 
axons in the ONH as the site of initial injury. 
Degeneration of axons occurred around 9-10 mos of age [8; 10; 12; 27]. The early 
signs of degeneration involved disorganization of the glial lamina, axon swellings, and 
the accumulation of organelles and neurofilament [12; 24]. These features were 
predominantly found in the glial lamina, prior to observations in other regions such as the 
distal optic nerve or NFL. Axon degeneration and gliosis followed with increasing 
disease severity.  
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D2: Effect of Bax-deficiency 
In human glaucoma, the loss of RGCs occurs through a programmed cell death 
pathway, apoptosis [31; 32]. RGC death may also result from secondary degeneration 
independent of apoptosis [33]. Apoptosis can be initiated through extrinsic receptor-
mediated signaling or intrinsic mitochondrial signaling pathways [34]. Intrinsic apoptotic 
initiation involves changes to the membrane permeability of mitochondria. The change in 
membrane permeability can permit the leakage of pro-apoptotic protein cytochrome c 
into the cytoplasm. Cytochrome c release is also regulated by the B-cell lymphoma (Bcl-
2) family of genes. Bcl-2 genes can be pro-apoptotic or anti-apoptotic. A Bcl-2 member 
gene, Bcl2-associated X protein (Bax) is pro-apoptotic and can initiate the release of 
cytochrome c from the mitochondria independent of mitochondrial membrane 
permeability [35; 36].  
The inhibition of Bax activity through transgenic lines carrying null alleles 
(D2.Bax-/- or 129 Sv/C57Bl/6J-Bax-/-), anti-sense oligonucleotides, or function-blocking 
peptides in mice or rats was shown to protect the RGC cell body from apoptosis in 
multiple models including D2, optic nerve crush, and axotomy [37-40]. However, the 
axons were not completely protected. Instead, axon degeneration appeared to be delayed, 
as determined by an upward shift in age in which a significant fraction of a cohort had 
severe degeneration [37]. A different model that induced RGC death through glutamate 
toxicity did not show any effects from Bax deficiency [37; 38]. Excitotoxicity may 
represent a model for secondary degeneration. The RGC loss in D2 is through an intrinsic 
apoptotic pathway, but axon degeneration occurs through a different pathway.  
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D2.Bax-/- mice were also used to support the theory that the ONH is the likely site 
of glaucomatous injury in D2 [12]. In Wallerian degeneration, axons proximal to a focal 
injury do not degenerate as long as the cell body survives, but axons distal to the lesion 
degenerate [41]. Since RGC bodies are preserved in D2.Bax-/-, optic nerves in late 
glaucomatous degeneration should survive to the point of the injury. Optic nerves with 
over 95% axon loss were selected for examination. Although there was massive loss of 
axons, there were surviving axons left at the anterior edge of the glial lamina. The site of 
injury most likely occurred at the glial lamina or very close to it.  
As a complementary experiment, the Slow Wallerian degeneration (Wlds) gene 
was crossed in the D2 strain (D2.Wlds) [12]. Wlds confers protection to axons after injury, 
but not to the cell body [42]. In D2.Wlds, there were much less severe cases of axon 
degeneration in 12-mo-old mice compared to D2 [12]. The number of surviving RGCs 
correlated well with surviving axons, though there were some reductions in soma size 
that suggested that the RGCs were not healthy. This experiment showed that protecting 
the axons from degeneration also preserved the RGC body.  
The use of the D2.Bax-/- demonstrated important concepts to understanding the 
biology of neurodegeneration in D2 [37; 43]. These findings may influence the research 
on neuroprotective strategies in human glaucoma. The first concept is that the factors 
leading to degeneration in the axons and in the RGC body are separable. This means that 
the development of therapeutic agents should be assessed for whether the agents would 
affect the axon or the RGC. Any injury models used should also consider whether the 
injury should affect the retina or optic nerve to assist in the interpretation of results. The 
second concept is that, as suspected in human glaucoma, the ONH sustains glaucomatous 
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injury before damage manifests in RGCs. It cannot be excluded that the soma may have 
an undetected injury that results in axon damage, but degeneration appeared first in ONH, 
specifically in the glial lamina.  
D2: Caveats 
The damage to D2 RGCs and the optic nerve is consistent with the damage 
observed in humans. But, it is unclear whether humans express the GpnmbR150X or Tyrp1b 
alleles. Pigmentary glaucoma is typically due to the iris rubbing against the anterior lens 
zonules, resulting in the liberation of iris pigments. Human glaucoma can result through 
different optic neuropathies and there are likely to be other genetic factors involved in the 
disease. Risk factors like angle closure or elevated IOP can activate pathways that are 
common to degeneration in both mouse and human. This makes D2 a useful model to 
study glaucoma, but D2 is still a mouse model. When possible, additional models should 
be used to validate the findings in D2.  
RGC and axon degeneration is eye-independent, variable, asynchronous, and 
progressive in D2. There is also some susceptibility of female D2 in developing iris 
defects and elevated IOP. These qualities can make it difficult to detect differences in an 
experiment, especially if the number of mice is limited or if the phenotype is subtle. It is 
important to consider the requirements for a sufficient sample size, to sex-match 
experimental groups and controls, and to determine the range of degeneration relevant for 
the study.  
Acute glaucoma models 
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Acute models of glaucoma can be useful for answering specific types of 
questions. Injuries can be applied to the optic nerve or retina directly and the resulting 
biology can be compared with what is known to occur in glaucoma. Laser 
photocoagulation and optic nerve crush are two alternative methods used in this thesis. 
These two methods, along with excitotoxicity, are briefly discussed. 
Laser photocoagulation 
Laser photocoagulation surgery typically utilizes an argon or diode laser to 
cauterize elements of the eye with the goal of reducing aqueous humor outflow. The laser 
can be aimed at a combination of the trabecular meshwork, episcleral veins, or limbal 
veins [44-52]. Outflow is stopped at the trabecular meshwork or after the aqueous humor 
exits Schlemm’s canal to join the circulatory system.  
The number of laser pulses applied, as well as the strength and duration of each 
pulse, can alter the effectiveness of the surgery. The pigmentation of the mouse is also a 
factor to consider; albino mice eyes absorb less energy than pigmented eyes and require 
different laser conditions [47]. IOP can increase between 4-48 hrs after surgery and stays 
elevated for some time before decreasing. Elevated IOP through laser surgery can lead to 
a sectorial pattern of degeneration similar to human glaucoma [46; 47; 49; 53]. 
Empirically-derived protocols need to take into account the particular types of equipment 
and mouse strains used, as well as the severity or time course desired, to produce 
consistent results [54]. A specific time course may be useful in studying therapeutic 
interventions.  
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Optic nerve crush or axotomy 
Optic nerve crush and axotomy are blunt procedures that crush or sever the optic 
nerve. Crush surgeries typically use self-closing or cross-action forceps that can apply a 
constant and consistent force onto the optic nerve [55]. The duration of the injury can be 
modified to induce more moderate or more severe damage. Retinal ischemia can be 
avoided as long as the duration is not too long and the site of injury is posterior to where 
the central retinal artery branches from the ophthalmic artery [16].  
The benefits of this technique are that it can be performed on any strain of mouse 
and the time that axons are damaged is known. Timing can be important in testing drugs 
to determine how quickly the optic nerve is expected to degenerate and whether a 
particular drug can slow degeneration. Direct damage results in axon degeneration, but 
there are axons that are initially spared which undergo secondary degeneration [56]. The 
study of secondary degeneration may be most useful in understanding how to preserve 
remaining axons in humans. Optic nerve crush and axotomy can also be used to 
investigate the effects of inflammation on the glia surrounding the injury site.  
Excitotoxicity 
It is controversial whether glutamate-induced toxicity is a primary factor in 
glaucomatous RGC death [33; 57; 58]. Excessive release of glutamate from axons and 
glia can result in calcium accumulation in astrocytes, oligodendrocytes, and NG2 cells. 
Calcium accumulation can cause apoptosis or necrosis to occur. In order to study how 
glutamate causes RGC death, glutamate, N-methyl-D-aspartate (NMDA), or kainic acid 
is injected intravitreally [54]. These ligands activate their cognate receptors and lead to an 
increase in intracellular sodium and calcium ions. Glaucoma has a distinct pattern of 
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RGC degeneration and the disease specifically affects RGCs. It is difficult to explain how 
these two features can be achieved through excitotoxicity from an invitreal injection.  
More recent work has introduced the possibility of local toxicity due to ectopic 
glutamate release from synaptic vesicles arising within the glial lamina after IOP 
elevation from a laser model [59]. Axon loss after laser-induced IOP elevation was 
attenuated when plugs containing drugs that block glutamate receptors and voltage-gated 
sodium channels were placed next to the ONH after surgery. Decreasing the amount of 
glutamate that might enter axons appeared to be neuroprotective. Ectopic glutamate 
release in the ONH provides a new target for understanding the involvement of 
excitotoxicity in glaucoma.  
Overview of astrocytes 
Astrocytes are present through the CNS and have a wide variety of functions [60-
69]. Astrocytes respond to early disease signals and might be informative in 
understanding the events that contribute to the progression of glaucoma [62; 70].  
Astrocytes can be identified by their expression of certain genes and their 
morphology. These markers should be used with caution however, because the location 
and physiological state of the astrocyte may influence which marker is expressed [66; 
69]. Other cell types may also express the same genes. Regardless, there are some 
common markers used to identify astrocytes in the CNS and ONH. These include 
cytoskeletal elements like GFAP, vimentin or nestin [71-73]; glutamate transporters like 
GLAST/EAAT1 and glial glutamate transporter GLT-1/EAAT2 [74]; and the more 
recently identified Aldh1L1 [75]. Other markers that have also been used to identify 
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astrocytes but may have less specificity are glutamine synthase [76; 77] and S100-β [78; 
79]. 
Types of astrocytes 
There are two broad categories of astrocytes that were identified by morphology 
and localization. These are protoplasmic astrocytes found throughout unmyelinated, grey 
matter and there are fibrous astrocytes that are found in white matter tracts [66]. 
Protoplasmic astrocytes have less glial filaments than fibrous astrocytes [80]. The optic 
nerve contains fibrous and protoplasmic astrocytes. Both types of astrocytes express 
GFAP when mature, but fibrous astrocytes can be differentiated from protoplasmic 
astrocytes through its reactivity against the antibody A2B5 and binding of tetanus toxin 
[81; 82]. A2B5 and tetanus toxin both bind to gangliosides that contain sialic acid 
residues on the cell surface. Fibrous astrocytes make up the majority of the optic nerve 
and protoplasmic astrocytes are concentrated in the nerve periphery. Protoplasmic 
astrocytes appeared to form the glia limitans, which is a component of the blood-brain 
barrier [81].  
The studies that characterized the protoplasmic and fibrous astrocytes were 
examined in transverse optic nerve sections [81; 82]. The studies showed that both 
astrocyte types were found in the optic nerve, but it was not clear whether there is greater 
segregation of astrocyte types in the pre-lamina or glial lamina, which contains 
unmyelinated axons, or in the MTZ, which contains a mix of unmyelinated and 
myelinated axons. In the brain, protoplasmic astrocytes have a regular, tiled formation 
[83] but the astrocytes in the glial lamina have greater overlap [15]. The astrocytes in the 
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glial lamina appeared to have a particular orientation that may be more informative of its 
function [15].  
Astrocyte morphology relates to function 
Astrocytes were named for their radial processes that stretch out into a star-shaped 
appearance. The processes of each astrocyte can extend in a predominately transverse, 
longitudinal, or random directions in the optic nerve [15; 84]. The discrete domains 
within the optic nerve may provide an environment that enables astrocytes to have lesser 
known activities. The morphology of astrocytes within the domains may be reflective of 
the functions required.  
Astrocytes surround axons in both the pre-laminar and laminar regions. In species 
with a lamina cribrosa, astrocytes line the pores and form a continuous glial sheath 
around each nerve bundle [85]. In mice, transversely-oriented astrocytes organize into 
glial columns that axons pass through, similar to the pores of the lamina cribrosa [12; 15]. 
The orthogonal orientation of axons to astrocyte processes and the reinforcement of 
multiple astrocyte processes contacting the axon bundle may provide greater structural 
stability to the axons and the optic nerve. The ‘honeycomb’ arrangement of the astrocytes 
was gradually lost as the axons became myelinated, suggesting that structural support 
from astrocytes may not be as necessary in the optic nerve as in the glial lamina.  
Transverse- and randomly-oriented astrocytes might interact with other cells, as 
well as with the blood supply. Astrocytes can form gap functions with one another [86; 
87], which allow calcium signaling through a population of connected astrocytes [63; 88]. 
This may allow astrocytes to rapidly respond to excitatory stimuli by increasing their 
uptake of neurotransmitters or to dilute the toxic effects of increased intracellular 
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calcium. The formation of finger-like projections of astrocytes might probe the 
environment at the nodes of Ranvier [89], which are the gaps that enable saltatory 
conduction located between segments of myelin. Astrocytes would be able to monitor the 
activity at the node as well as remove neurotransmitters that might be released by the 
axon [59; 90]. Optic nerve astrocytes also form end-feet on blood vessels and the pia 
mater [15]. The astrocyte end-feet contribute to the integrity of the blood-brain barrier 
and this association allows astrocytes to transport nutrients and ions in from the vascular 
system, transport waste products out of the vascular system, and regulate blood blow to 
neurons [63; 91].  
Longitudinal astrocytes, found more often in the MTZ or myelinated optic nerve 
[15], might be better suited to monitor the health of a bundle of axons. The astrocyte may 
also exchange signals from the myelin sheaths that cover the axons. Astrocytes might 
therefore be sensitive to injuries in axons and myelin.  
Astrocytes may be oriented in any direction in the optic nerve, but appear to have 
some specificity in having a transverse orientation in the glial lamina. Astrocytes have 
multiple processes that would enable many types of interactions, which may explain how 
astrocytes can be involved in so many functions.  
Astrocyte reactivity to optic nerve injury 
In disease or injury, astrocytes become reactive by increasing the expression of 
different genes controlling cytoskeletal elements, changing their cellular morphology, 
expressing cytokines or growth factors and their receptors, and forming a glial scar at the 
site of injury [63; 69; 92-94]. Increase of intermediate filaments GFAP and vimentin 
expression is common in reactive astrocytes, especially when the astrocyte processes 
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thicken to form a glial scar. Astrocyte can produce cytokines and neurotrophic factors 
and their receptors after injury [69]. This might result in pro- or anti-inflammatory 
molecules, depending on the context of the astrocyte [93]. The glia scar can include other 
glia, such as NG2-expressing cells [95], extracellular matrix proteins such as chondroitin 
sulfate proteoglycans [96], and myelin proteins like myelin-associated glycoprotein 
(MAG) [97]. These elements can physically block axons from innervating its target and 
prevent axon and myelin regeneration [62; 68; 94; 95; 98].  
Astrocytes appear to be the primary mediators of scar formation in the brain and 
spinal cord after traumatic injuries or a multiple sclerosis model, experimental 
autoimmune encephalomyelitis (EAE) [93]. A transgenic mouse was generated to express 
herpes simplex virus thymidine kinase (HSV-TK) under the GFAP promoter [99; 100]. 
When cells expressing HSV-TK are exposed to an antiviral prodrug, in this instance a 
guanosine analog ganciclovir, there is a kinase cascade that results in phosphorylation of 
ganciclovir [101]. Once it is incorporated into DNA, new nucleotides cannot be added to 
the DNA strand. This model allowed the direct ablation of astrocytes after an injury 
[100]. Without proliferating astrocytes after injury, scar formation was disrupted. The 
absence of scar formation resulted in the spread of inflammation, persistence of a broken 
blood-brain barrier, increased damage and degeneration, and impaired recovery [93].  
The reactivity of astrocytes is proposed to be a graded response, one that is 
reflective of the severity of the injury [93]. Astrocytes did not appear to proliferate after 
acute models of glaucoma [102; 103], although a scar was formed when the optic nerve 
was crushed [102]. Astrocyte proliferation was observed during axon degeneration in D2 
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mice [104]. This reflects the heterogeneity in the astrocyte response to injury and also 
emphasizes the importance of the context of the injury.  
A less severe injury may result in short-term hypertrophy that can resolve with 
time [93; 103]. When IOP was transiently elevated for 1 hr through cannulation with 
saline, ONH astrocytes retracted their processes and the organization of the glial lamina 
was disrupted within 3 days [103]. The astrocyte processes became thicker and less 
complex, with hypertrophy of the astrocyte soma. The transient IOP elevation did not 
result in axonal degeneration, or apoptosis or proliferation of astrocytes. The morphology 
of the astrocytes appeared to be recovered by 6 weeks after IOP increase and the 
honeycomb appearance of the glial lamina was restored. A graded response would be 
beneficial to cells and tissue, especially in the case of eyes, which are subject to daily 
fluctuations in pressure [105]. Large fluctuations in IOP of glaucoma patients was 
correlated with increased vision loss, even though the long-term mean IOP was within a 
normal range [106]. Less severe insults would be manageable without the formation of a 
glial scar that could cause future impairments. 
In an optic nerve crush, which causes direct damage to axons, fibrous astrocytes 
had a biphasic reaction where they retracted their processes within 3 days, gradually re-
extended their processes after 1 week, and formed a glial scar within 2 weeks [102]. The 
glial tubes that make up the honeycomb appearance of the normal glial lamina were not 
restored; this may be due to the absence of axons. There was also lost contact between 
other cells, blood vessels, and the pia. Some contact with blood vessels and the pia were 
re-established. The reduced interaction with the circulatory system may have long-term 
effects on the optic nerve.  
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In contrast to the pronounced retraction of branching of optic nerve astrocytes 
after crush injury, protoplasmic astrocytes in the cortex have increased branching after a 
traumatic stab lesion [102], while astrocytes in D2 mice had a modest decrease [107]. 
Astrocytes in glaucomatous D2 had less complex ramification of their processes and the 
processes that remained were thickened. These differences reflect the different responses 
by particular types of astrocytes. Astrocytes in D2 may undergo a biphasic morphological 
response, but the transition may be transient [107]. Prior to axon loss, transversely-
oriented astrocytes appeared to have localized remodeling by the formation of 
appendages that extended longitudinally into axon bundles [107]. The appendages were 
not formed from all the processes, suggesting that they may have reacted to early signs of 
axonal damage.  
Overview of microglia 
Microglia are the resident phagocytes of the CNS. Microglia can be identified 
through many of the same markers that label macrophages. This can include expression 
of CD68, Iba1, and Lgals3. These markers cannot distinguish resident microglia from 
infiltrating phagocytes. Microglia can become more amoeboid after activation [108], but 
this morphology might suggest also a resting microglia [109] or an invading phagocyte 
[110]. It can be difficult to distinguish microglia from macrophages or reactive and non-
reactive microglia, so it is important to be aware of the context in which the cells 
examined.  
Microglia have thin, ramified processes that are used to continuously monitor the 
local neuronal environment [111]. Disruption of the blood-brain barrier through a focal 
laser-mediated lesion in the brain drew a rapid and localized response of microglia to the 
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site of injury [111]. Microglia with increased ramification appeared to enwrap the lesion 
in the blood vessel with processes, which had an effect of shielding the lesion from the 
surrounding tissue. Acute injury or neurodegenerative disease can result in Wallerian 
degeneration, which is when the axon degenerates away from the cell body, or axonal 
dieback, which is when the axon degenerates towards the cell body. The removal of the 
axonal fragments can be performed through the phagocytic activity of phagocytes like 
microglia or macrophages [112; 113]. The response of microglia to injury or disease 
includes participation in glial scar formation, phagocytic activity, morphological changes, 
proliferation, and cytokine release [98; 112; 114].  
Microglia are phagocytic and induce oxidative stress 
Activated microglia were found to be involved in inflammation within the 
substantia nigra of patients with Parkinson’s disease (PD) [115]. It was hypothesized that 
dying neurons might release alpha synuclein (Snca) into the extracellular space, which 
would subsequently be phagocytosed by microglia, and then lead to chronic inflammation 
due to cytokine release by microglia [116]. Snca, which forms aggregates in the Lewy 
bodies found in PD and dementia with Lewy bodies, appeared to activate cultured 
microglia [116]. The internalization of Snca led to the release of reactive oxygen species 
(ROS) in the culture media. ROS can damage lipids, proteins, and DNA, which can result 
in degeneration of the cell [117; 118]. The deletion of the enzyme that generates ROS in 
phagocytes, NADPH oxidase [119], resulted in less ROS production and less toxicity to 
neurons in response to Snca internalization by microglia [116]. 
Microglia also cause inflammation after the secretion of cytokines in response to 
certain types of injuries [112; 120]. In demyelinating diseases like multiple sclerosis, 
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lesions contained microglia, fragments of myelin, and inducible nitric oxide synthase 
(iNOS) [121]. Nitrogen oxygen species such as nitric oxide are produced by iNOS. The 
cells that produced iNOS were microglia and, infrequently, the astrocytes surrounding the 
lesion. Microglia that phagocytosed myelin in vitro also expressed iNOS [122]. These 
cells released TNFα, which is a pro-inflammatory cytokine, and glutamate after myelin 
internalization. TNFα and glutamate release could result in local inflammation and 
glutamate toxicity to surrounding glia and neurons. Nitric oxide reacts with superoxide to 
form a free radical that damages cell membranes of phagocytes and astrocytes [123]. 
Myelin and axons were also affected by oxidative damage [124].  
Studies in the PNS have demonstrated that macrophages express Mac-1, Mac-
2/Lgals3, the Fc receptor, and F4/80 during Wallerian degeneration [125]. The expression 
of Lgals3 appeared to be specifically expressed when macrophages were phagocytosing 
myelin; Lgals3 was also seen in phagocytic Schwann cells [125]. In cultured microglia, 
myelin was phagocytosed and each of the phagocytic markers were expressed by 
microglia [126]. Astrocytes co-cultured with microglia and did not demonstrate any 
phagocytic activity. However, in optic nerves, the expression of the phagocytic markers 
was highly variable after axotomy. Microglia did not appear to efficiently remove myelin 
in the optic nerve even though there was acute damage to the axons.  
Microglia in optic neuropathy 
The slow removal of myelin after injury was observed after axotomy and 
enucleation in rodents [126-129]. Indeed, myelin debris persisted for months in the optic 
nerve despite the presence of phagocytic microglia. Microglia could have early but brief 
periods of phagocytosis that occurs asynchronously, which might explain the variable 
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expression in injured tissue. The phagocytosis of myelin was proposed to lead to 
inhibition of further phagocytic activity in microglia and macrophages [130]. This could 
result in an early deactivation of phagocytosis. 
The involvement of cytokines and ROS in glaucoma is unclear. Inflammation is 
not a typical sign of POAG or PACG. Microglia from glaucomatous human optic nerves 
were reported to produce cytokines [131], TNFα [132; 133], and nNOS, iNOS, and eNOS 
[134]. However, increased iNOS was not reproduced in a different study of human optic 
nerves [135]. There also did not appear an increase in iNOS production in the optic 
nerves of two rodent models of glaucoma [135; 136]. The technical differences in tissue 
preparation and small sample size of human tissue may have contributed to difference in 
the conclusions of iNOS labeling in human tissue [135]. The animal models used may not 
be similar to human disease in regards to iNOS expression.  
In human glaucoma [108] and in the D2 model [104; 137], microglia appeared 
more abundant using cell markers in the ONH. However, this may have been due to the 
redistribution or movement of microglia to a site of injury. Microglia were not observed 
to proliferate, as measured by the incorporation of a synthetic nucleoside used to label 
replicating deoxyribonucleic acid [138]. 
Unexpected behavior of glia may be driven by specific local cues 
Microglia and astrocytes most likely play important roles in glaucoma, but the 
roles may not be identical to the roles for those cells elsewhere in the nervous system. 
The deficiency of myelin internalization, the uncertainty of ROS production, and the 
possibly non-proliferative nature of microglia in glaucomatous optic nerves suggests that 
optic nerve microglia have different roles in the optic nerve than they do in the brain. 
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Astrocytes are capable of a wide variety of functions and may perform functions similar 
to microglia. The different types of damage that might result in the development of 
glaucoma might elicit different reactions from the resident glia. This thesis will examine 
the novel role of phagocytosis by astrocytes in the ONH.  
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Chapter 2: Phagocytic astrocytes in the optic 
nerve head internalize gamma synuclein spheroids 
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Chapter 2 is based on results from the following publication: 
Nguyen JV, Soto I, Kim KY, Bushong EA, Oglesby E, Valiente-Soriano 
FJ, Yang Z, Davis CH, Bedont JL, Son JL, Wei JO, Buchman VL, Zack DJ, 
Vidal-Sanz M, Ellisman MH, Marsh-Armstrong N. Myelination transition zone 
astrocytes are constitutively phagocytic and have synuclein dependent reactivity 
in glaucoma. Proc Natl Acad Sci U S A. 2011 Jan 18;108(3):1176-81. 
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were data generated by co-authors and previously published.  
Figure 2.9A (EO, FJV-S) and Figure 2.9B (CD, ZY) were performed by co-authors and 
analyzed by JVN.  
Figures 2.1; 2.2A, B; 2.6C were experiments of published and unpublished data 
established by co-authors performed by JVN.  
Figures 2.3; 2.4; 2.5; 2.6A, B were original data generated by JVN. 
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Introduction 
The synucleins form a family of genes that are primarily expressed in the nervous 
system. The first synuclein was identified in the electric ray Torpedo californica. T. 
californica have a high density of cholinergic neurons in the electromotor nucleus that 
synapse onto the electric organ [139]. The synapses are enriched for proteins involved in 
synaptic transmission and neurotransmitter metabolism, which enable the ray to produce 
electric shocks. Cholinergic synaptic vesicles were purified from the electric organ in 
order to produce antisera that would be able to identify vesicle-specific proteins [140]. It 
was this antisera that was used to identify Synuclein (Syn), so named because of its 
localization to the presynaptic terminal of the electric organ and to a portion of the 
nuclear membrane [141]. A homolog of Syn was also found in rat brain (rtSyn) and 
included two splice variants [141; 142]. In the rat brain, rtSyn was concentrated in the 
cerebral cortex, hippocampus, and dentate gyrus, but was also expressed in other regions 
[142]. 
The synuclein family of genes has expanded to include three members that are 
conserved among vertebrates: alpha (Snca), beta (Sncb), and gamma (Sncg) synuclein. 
Further sequencing of synucleins in different animals led to the conclusion that rtSyn was 
an ortholog of Snca, but Syn isolated from T. californica was an ortholog of Sncg [141-
144]. While the N-termini of the synuclein genes have high sequence similarity, the C-
termini have more sequence variability. This suggests that the synucleins might have 
similar functions, but their specific roles are regulated by their unique C-terminus. The 
differences in protein localization may also affect their function. Snca has been widely 
studied and serves as the framework of how we approached our study of Sncg.  
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The discoveries that linked Snca with neuropathology were from peptide 
sequences and proteins identified in amyloids from the brain tissue of Alzheimer’s 
disease patients [145; 146]. Antibodies generated against two peptide sequences, 
sequences which were later identified to be a tandem sequence, localized to amyloid 
fibrils [145]. The tandem sequence, named non-A beta component (NAC), was not a 
known component of the amyloids or neurofibrillary tangles that were typical of AD. A 
cDNA screen identified a gene sequence that contained NAC as a centrally located, 
hydrophobic domain. This gene was named non-A beta component of AD amyloid 
precursor (NACP). In an independent and later study, NAC was shown to play a role in 
Snca fibrillization [147]. The second independent identification of Snca in AD was 
through the use of an antibody that recognized hyperphosphorylated tau in neurofibrillary 
lesions [148]. This antibody identified two additional proteins that were of a lower 
molecular weight than tau [146]. One protein was matched to Ueda, et al.’s NACP 
sequence and the other protein was homologous to bovine phosphoneuroprotein 14. The 
similarity of these genes led to the grouping of the genes as a family. NACP was renamed 
Snca and the homolog to bovine phosphoneuroprotein 14 was named Sncb [146]. 
The initial characterizations that demonstrated Snca localization suggested that it 
would be involved in synaptic transmission [141]. Studies of Snca in Taeniopygia 
guttata, the zebra finch, also showed that the majority of Snca in the molecular layer of 
the cerebellum colocalized with the synaptic vesicle membrane protein synaptotagmin 
[149; 150]. The role of Snca in synaptic transmission was confirmed when Snca was 
discovered to have chaperone activity by binding to synaptobrevin-2 to promote the 
assembly of soluble N-ethylmaleimide-sensitive factor attachment protein receptors 
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(SNAREs) [151]. Snca may regulate the pools of recycled synaptic vesicles in the 
presynaptic cleft by preventing reclustering of recycled vesicles or affecting the 
trafficking of other presynaptic proteins [152-154]. Reductions in the recycling pool 
result in less neurotransmitter release and neuronal signaling [152], which can contribute 
to degeneration of the synapses [155].  
The structure of Snca is natively unfolded but Snca can form oligomeric 
intermediates and then fibrils [156]. Snca fibrils can be found in fibrillary tangles, Lewy 
bodies, and insoluble inclusions in neurodegenerative diseases. The involvement of Snca 
in fibrils and proteinase K (PK) insoluble inclusions [157; 158] have suggested that Snca 
aggregation is pathogenic. However, some studies suggest that the fibrils are protective 
and that oligomeric intermediates pathogenic [159-162].  
The final member of the synuclein family is Sncg. It was identified in a cDNA 
screen that sought to discover genes that were differentially expressed in breast cancer as 
compared with normal breast tissue [163]. Sncg overrides the spindle checkpoint in 
mitosis by inhibiting the kinase BubR1 [164-166]. This allows cells to exit mitosis 
without appropriate chromosome segregation and enables the proliferation of cancerous 
cells.  
The role of Sncg in the nervous system is less clear. Sncg was identified in an in 
silico screen that was searching for genes that might be involved in Parkinson’s disease 
(PD) due to its similarity to Snca or that might interact with Snca [167]. Sncg was found 
in various regions of the brain, but was more highly expressed in motor and sensory 
neurons [168]. Sncg has not yet been found in Lewy bodies or senile plaques [169]. 
Instead, it has been found as spheroidal inclusions in dementia with Lewy bodies- and 
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PD-affected hippocampus [169], neurodegeneration with brain iron accumulation, type - 
1-affected brain [170], and optic neuropathy-affected optic nerve [171; 172]. Sncg can 
localize to the synapses, cytoplasm, or axons of neurons [168]. This additional 
localization may be informative of the different roles Sncg might perform. 
Sncg is highly expressed in the cell body and axons of retinal ganglion cells 
(RGCs) [10; 172]. The formation of spheroids in the optic nerve suggests that Sncg might 
reflect pathology in the retina and optic nerve similar to Snca in the brain. PK-resistance 
of Snca and Sncg is related to aggregation and fibrillization, both of which typically 
occurred with the overexpression of the protein [173; 174].  
Overexpression of Sncg in neurons (C57Bl/6J-Thy1-mγSN) had a pathological 
effect on specific types of neurons. Increased Sncg expression in motor neurons was 
followed by loss of motor neurons, neurological and motor defects, as well as Sncg 
spheroids [174; 175]. Symptoms were progressively worse with age. Sncg expression 
was increased in the retina, but there was no degeneration of RGCs or optic nerve axons 
in 12-mo-old C57Bl/6J-Thy1-mγSN [175].  
Deletion of Sncg in mice did not appear to affect the numbers of motor neurons, 
sensory neurons, or RGCs [11; 176]. Changes in Sncg expression levels have thus far 
been reported to be overexpressed in metastatic cancer cells [163; 177-180] and 
decreased in the DBA/2J (D2) mouse and a rat model of IOP elevation [10; 171]. The 
effects of Sncg overexpression or deletion may be subtle or there may be compensation 
by Snca or Sncb, and the relevant model to study it in is not clear.  
I propose that Sncg spheroids form as a result of axon degeneration and not Sncg 
overexpression. Therefore, Sncg was used as a marker for RGCs and axons in the 
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following experiments, and not to investigate the function of Sncg. Axon degeneration 
was studied in the D2 mouse glaucoma model. This is because D2 mice develop many of 
the same signs found in human glaucoma, including elevated IOP and loss of axons and 
RGCs in a distinct pattern [9; 24]. Degenerated D2 optic nerves also contained Sncg 
spheroids, similar to that seen in human optic neuropathy [171; 172]. Sncg spheroids 
appeared during a period of degeneration where sectorial loss of axons occurred and 
became more apparent as more axons degenerated. A novel function of optic nerve 
astrocytes was revealed when we discovered that astrocytes internalized Sncg and axonal 
spheroids.  
 
Results 
Sncg, a marker for RGCs, forms spheroids in glaucomatous optic nerve 
We detected different extents of degeneration in 10-mo-old D2 retinas through in 
situ hybridization using Sncg messenger RNA (mRNA) probes and in optic nerves using 
immunofluorescence. For simplicity, these extents were categorized in three stages here. 
Retinas without signs of degeneration (No noticeable degeneration, NND) contained 
RGCs distributed throughout the tissue (Figure 2.1A, left). In sectorial degeneration, 
wedge-shaped regions of RGC death were observed, and in late degeneration, there were 
few RGCs remaining (Figure 2.1A, center, right). 
Transverse sections of optic nerve were labeled with an antibody generated 
against the last 16 amino acids (aa) of the C-terminus of mouse Sncg (Sncgaa108-123) 
(Figure 2.2A). This antibody colocalized with an antibody for an axonal cytoskeletal 
marker, pNF. Both antibodies reported surviving axons in different stages of optic nerve 
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degeneration and can be correlated with RGC degeneration [46]. With NND, axons were 
distributed throughout the optic nerve. In sectorial degeneration, there were regions of 
axon loss. In this particular example, axons were lost in a peripheral region of the optic 
nerve. A second region containing an intermediate density of axons was also observed. 
These two regions of axon loss were also visible in longitudinal sections of ONH taken 
from the same optic nerve (Figure 2.2B). As axon loss was observed, Sncg also appeared 
to form spheroids. Nerves in late degeneration had little axonal labeling by pNF and 
Sncg, but Sncg continued to label spheroids and also labeled glia.  
The glia labeled by Sncg in late degeneration were oriented transversely and 
longitudinally, and extended multiple fine processes from the cell body (Figure 2.2A, B). 
This morphology was consistent with published descriptions of optic nerve astrocytes 
[15; 84; 89; 107]. The glia were identified as astrocytes through colocalization with 
Vimentin mRNA and association with blood vessels [11].  
The Sncg spheroids in sectorial and late degenerated nerves (Figure 2.2B, D) 
varied in size from ~1-4um. Some spheroids appeared to be continuous with axons while 
others were completely separated from axons (Figure 2.2D). This suggested that the 
spheroids were axon swellings that separated from the axon. Spheroids were located 
inside and outside of regions with severe axonal degeneration. Sncg+ astrocytes and Sncg 
spheroids have been reported in late stages of optic nerve degeneration in humans and a 
rat model of glaucoma [171], but not in optic nerves taken from eyes with retinoblastoma 
[172]. The formation of Sncg spheroids may only result in certain types of diseases 
related to optic neuropathies, but not diseases of the retina. Sncg spheroids were present 
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in D2 as well, suggesting that the presence of Sncg labeling outside of axons may be a 
pathological phenotype of a disease that affects the optic nerve. 
Microglia activation in D2 mice 
Microglia are resident phagocytes that can be identified through Iba1 
immunoreactivity [181] and appeared to be reactive in glaucomatous D2 optic nerves 
[182]. Microglia in 10-mo-old control DBA/2J-Gpnmb+/Sj (D2-Gpnmb+) ONH were 
oriented longitudinally with short ramified processes (Figure 2.3A). Microglia were 
hypertrophic with thickened processes in 10-mo-old D2 ONH (Figure 2.3C). The change 
in morphology suggests that microglia may be producing an inflammatory response to 
degeneration [183] or that microglia may also participate in phagocytic clearance of 
damaged cells or axons [112]. 
The immunoreactivity of Iba1 was quantified and analyzed using multiple 
segmentation values (MSV) (Experimental Materials and Methods). With MSV, the 
immunoreactivity was measured at multiple fluorescence thresholds. The signal intensity 
from each threshold was averaged using multiple sections per optic nerve and multiple 
optic nerves per genotype. Two-tailed Student’s t-test assuming unequal variances 
(Welch’s correction) identified segmentation values (SV) in which there was a 
statistically significant difference (p < 0.005) in Iba1 expression in 10-mo-old D2 (N = 
11; x̄ sections quantified = 11) compared to D2-Gpnmb+ (N = 13; x̄ sections quantified = 
13). This method was used to identify a mean fold-change in expression that was more 
representative of the data.  
SV with significant differences are marked by the shaded region in the graph 
(Figure 2.3B). Iba1 expression within this range increased by a mean fold-change of 2.3 
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± 0.02 SEM. SV1010 was closest to the mean fold-change. At SV1010 for Iba1, D2-
Gpnmb+ = 9.6 ± 1 SEM and D2 = 22.3 ± 3, p = 0.001 in a two-tailed, unpaired t-test with 
Welch’s correction.  
Protease-resistant Sncg in the optic nerve and retina 
In human diseases and mouse models of synucleinopathies, Snca is misfolded, 
forms fibrils, and becomes protease-resistant [157; 158]. The pre-treatment of cortical 
tissue containing Lewy bodies with PK diminished the reactivity of an antibody against 
the N-terminus of Snca, but did not diminish the reactivity of an antibody against the C-
terminus [184]. This suggested that the C-terminus of Snca was PK-resistant when 
incorporated into fibrils. Furthermore, pre-treating tissue from samples affected with 
progressive supranuclear palsy, corticobasal degeneration, and Pick’s disease using PK 
revealed immunoreactivity by the C-terminal Snca antibody that was not observed prior 
to PK treatment [185]. It appeared that the C-terminal Snca epitope was revealed after 
other proteins were proteolyzed. We compared our C-terminal Sncg antibody against a 
commercial Sncg antibody covering the majority of the human Sncg sequence (Sncgaa21-
127) to determine whether glaucomatous retina or optic nerve would also show selective 
immunoreactivity to a C-terminal Sncg antibody, with or without PK treatment.  
The two Sncg antibodies were first tested for specificity in Sncg-/- tissue. There 
was no specific reactivity in the retinas or optic nerves of knockout mice, but there was 
reactivity in wildtype mice [11]. Then they were tested for epitope specificity. Cultured 
cells were transfected with a plasmid to overexpress all 123 aa of mouse Sncg or aa 1-108 
(deleting the last 15 aa) of mouse Sncg (Figure 2.4A). The Sncg gene was fused with 
GFP in order to identify cells that were transfected. Sncgaa21-127 antibody detected all 
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transfected cells. Sncgaa108-123 antibody detected full-length Sncg, but not the truncated 
form.  
After the antibodies were validated, sagittal retina sections were labeled with both 
Sncg antibodies (Figure 2.4B). PK treatment abolished the staining of Sncgaa21-127 and 
Sncgaa108-123 antibodies in non-diseased retinas, however PK treatment selectively 
abolished staining by Sncgaa21-127 in diseased retinas. Sncgaa108-123 labeled glia in the inner 
plexiform layer (IPL) that was not specific to GFAP+ astrocytes or CD45+ microglia [11] 
in degenerated 10-mo-old D2 retinas. These findings suggest that glaucomatous damage 
affects the epitope exposure of Sncg. PK treatment in the ONH demonstrated similar 
labeling of axons, astrocytes, and spheroids by the C-terminal Sncg antibody in diseased 
tissue (Figure 2.2B). Irregular Sncg labeling in astrocytes and spheroids in glaucomatous 
retinas and optic nerves were PK-resistant and selectively labeled using an antibody 
against the C-terminus.  
Phagocytic genes expressed by astrocytes in ONH 
Microglia in the ONH had increased Iba1 expression and morphological changes 
with degeneration. The appearance of Sncg spheroids in degeneration might induce 
microglial activation and also be phagocytosed by microglia to clear the material from 
the extracellular space. A second marker for microglia, Lgals3, was previously shown by 
our group to express in Iba1+ microglia in distal optic nerve during late degeneration in 
D2 [104]. In the ONH, Lgals3 was immunoreactive in 10-mo-old D2-Gpnmb+ and D2 
but there was little colocalization with Iba1 signal (Figure 2.3A, C). The identity of the 
cells that expressed Lgals3 in the optic nerve without Iba1 expression was determined 
through colocalization of mRNA probes in situ for astrocyte markers Vimentin and 
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Aldh1L1 [11]. Lgals3 was also expressed by GFAP-expressing astrocytes in C57Bl/6J 
and in GFP+/GFAP+ astrocytes from a transgenic mouse expressing enhanced GFP under 
the astrocyte promoter GLT-1 (Figure 2.5A, B). Lgals3 expressed in cells that were 
labeled by different markers for astrocytes and in multiple mouse genotypes. 
A transcriptome analysis using microarrays identified several genes involved in 
the phagocytosis and engulfment of apoptotic cells that were expressed by astrocytes 
obtained from mouse forebrain [75]. These genes, including Lrp1, Abca1, and Mfge8, 
were members of two evolutionarily conserved phagocytic pathways initiated by either 
CED-1/Lrp1 or CED-2/CrkII [186]. Lrp1 and Abca1 are part of the CED-1/Lrp1 
engulfment pathway. Mfge8 is a secreted opsonin that can bridge phosphatidylserine on 
an apoptotic cell to engulfment receptors on a phagocyte’s cell membrane [187]. We 
examined Lgals+ astrocytes for expression of these markers involved in the phagocytic 
pathways by in situ hybridization and found that Lrp1, Abca1, and Mfge8 were indeed 
expressed by Lgals3+ astrocytes [11]. Astrocytes in the ONH thus express genes 
associated with phagocytic activity and may also perform phagocytic functions.  
Lgals3 expression peaks in the MTZ in the optic nerve 
Lgals3 expressed in the optic nerve, but excluded the glial lamina. It was highly 
expressed in the adjacent myelination transition zone (MTZ), where axons become 
myelinated (Figure 2.6A). The localization of Lgals3 expression was also examined 
relative to the position of oligodendrocyte marker Proteolipid protein. This showed that 
Lgals3 expression began where oligodendrocytes appeared most anteriorly in the nerve 
[11]. In late degeneration, Lgals3 reactivity was localized throughout most of the 
longitudinal section (Figure 2.6C) and did not appear to correlate with regions of axon 
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loss (Figure 2.4A, C). This variable expression was similar to observed Lgals3 
expression in microglia after optic nerve transection [126]. These results suggest that 
Lgals3 might be reactive to stimuli other than actively degenerating axons. 
Lgals3 immunoreactivity was quantified by MSV using multiple cohorts of mice. 
The mean fold-change ranged from 2-25 times higher in 10-mo-old D2 compared to 3-
mo-old D2 [11] or age-matched D2-Gpnmb+ (Figure 2.6B). In one quantification of 
Lgals3 (Figure 2.6B, top), the shaded region contains values where p < 0.01 between 
D2-Gpnmb+ (N = 8, x̄ sections quantified = 7) and D2 (N = 6, x̄ sections quantified = 4). 
The calculated mean fold-change was 25 ± 3 SEM. At SV400, D2-Gpnmb+ = 0.7 ± 0.1 
SEM and D2 = 18.2 ± 3.8, p = 0.006 in a two-tailed, unpaired t-test with Welch’s 
correction.  
In a second cohort of 10-mo-old mice D2, the shaded region contains values 
where p < 0.005 between D2-Gpnmb+ (N = 11, x̄ sections quantified = 11) and D2 (N = 
13, x̄ sections quantified = 13) (Figure 2.6B, bottom). The calculated mean fold-change 
of Lgals3 was 2 ± 0.07 SEM. At SV370 for Lgals3, D2-Gpnmb+ = 42.0 ± 4.8 SEM and 
D2 = 82.8 ± 10.1, p = 0.002 in a two-tailed, unpaired t-test with Welch’s correction.   
The variability in mean fold-change calculated here may be due to technical 
differences introduced during the time between each of these analyses was performed. 
Modifications made to image acquisition and data analysis also could affect the absolute 
measure of fluorescence intensity. There are also inherent differences in Lgals3 
expression, especially with the knowledge that D2 within each of our cohorts have 
different extents of degeneration. In addition to the immunofluorescence data presented 
here, western blot of D2 ONH showed variable expression in ONH with degeneration 
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(Chapter 3 Results). Lgals3 mRNA expression was also increased in microarrays using 
D2 ONH [188-190]. Despite variability, Lgals3 expression was increased in a population 
of aged D2 mice in multiple cohorts and in different experimental approaches.  
Lgals3+ astrocytes phagocytose Sncg structures  
Sncg spheroids were more frequently found in the MTZ, where constitutive 
Lgals3 expression was highest. Lgals3+ astrocytes in the MTZ were therefore examined 
for possible interactions with Sncg spheroids. In both 3-mo-old and 9-mo-old D2 optic 
nerves, Sncg structures were found in close contact with Lgals3-expressing astrocytes 
(Figure 2.7A). Some structures were also fully enclosed by the cytoplasm, as seen by 
confocal microscopy (Figure 2.7B). Lgals3+ astrocytes appeared to phagocytose Sncg in 
both young and old D2 mice.   
Astrocytes are phagocytic in normal ONH 
To determine whether astrocytes were phagocytic in other mouse strains, we 
examined the ultrastructure of a 9-mo-old C57Bl/6J mouse optic nerve using serial 
blockface scanning electron microscopy (SBEM). Astrocytes throughout the ONH 
showed evidence of axons and debris (Figure 2.8). Granular material and vesicles were 
accumulated within an axon swelling and formed a protrusion into an astrocyte (Figure 
2.8, left panels). Debris with a similar appearance were also completely detached from 
axons with a membrane containing the debris (Figure 2.8, center panels). It was 
determined that these evulsions of detached axonal material were completely enclosed 
within astrocyte cytoplasm after examination of serial sections. Other debris found inside 
astrocytes did not have a membrane separating the debris. This absence of the membrane 
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suggested that the envelope of axon membrane containing the debris was degraded by the 
astrocyte (Figure 2.8, right panels).  
The quantification of debris in a subvolume within the glial lamina and MTZ 
resulted in 218 objects counted in the glial lamina and 72 objects in the MTZ [11]. The 
mean radius of objects within these regions was similar, averaging 1µm, but there was 
higher variability in the MTZ [11].  However, the glial lamina was narrower in diameter 
than the MTZ. This difference may influence the number of objects found per unit area 
and might not be reflective of the region as a whole. SBEM revealed the formation of 
axonal debris in a 9-mo-old C57Bl/6J ONH that did not have signs of degeneration. 
There may be increased axonal debris formation in the glial lamina and astrocytes within 
the glial lamina and MTZ internalized axonal material. 
Effect of Sncg on Lgals3 reactivity after laser photocoagulation or optic nerve crush 
The phagocytic activity of astrocytes in the ONH, the phagocytosis of Sncg 
structures by Lgals3+ astrocytes, and the particular localization of Sncg spheroids and 
Lgals3 in the MTZ led us to consider whether Sncg may be involved in the increased 
Lgals3 expression in diseased tissue. Translimbal laser photocoagulation is a model for 
glaucoma that uses a laser to cauterize the translimbal and/or episcleral blood vessels of 
the eye and prevent the outflow of the aqueous humor [45; 47-50; 52; 191]. This leads to 
elevated IOP and can result in axon degeneration and RGC loss. IOP was unilaterally 
increased in Sncg+/- (N = 11, x̄ sections quantified = 7) and Sncg-/- (N = 11, x̄ sections 
quantified = 4) mice. IOP increased from 15mm Hg to 30mm Hg by 24 hours after 
surgery in the affected eye [11]. The average IOP remained elevated in treated eyes at 
day 7 after surgery. Elevated IOP was not observed in untreated eyes [Sncg+/- (N = 7, x̄ 
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sections quantified = 8) and Sncg-/- (N = 11, x̄ sections quantified = 6] at any time point 
after surgery. It did not appear that the absence of Sncg influenced IOP elevation. 
Although there was sustained IOP elevation in treated eyes in this cohort, there were no 
large regions of RGC loss [11].  
Analysis of Lgals3 expression by MSV in the ONH showed that Lgals3 had a 
slight increase in the Sncg+/- lasered condition, but had a limited increase in Sncg-/- 
(Figure 2.9A). There were only 2 SV that reached a significant difference by t-test when 
comparing lasered Sncg+/- and lasered Sncg-/-. Analysis by t-tests to estimate mean fold-
changes were not implemented at the time this data was published [11].  
An axon injury model where the optic nerve was crushed was also used to study 
Lgals3 expression in Sncg+/- (crushed N = 6, x̄ sections quantified = 9; uncrushed N = 6, 
x̄ sections quantified = 5) and Sncg-/- (crushed N = 7, x̄ sections quantified = 7; uncrushed 
N = 6, x̄ sections quantified = 6) optic nerves. At the crush site, which was approximately 
1-2mm posterior to the eyeball, there were amoeboid cells highly reactive for Lgals3 
(Figure 2.9B). The morphology and localization suggested that the amoeboid cells were 
microglia or infiltrated macrophages. 
Because the expression of Lgals3 in astrocytes was of interest, Lgals3 expression 
was measured in the MTZ astrocytes anterior to the crush site. ONH was labeled with 
Lgals3 and GFAP+ antibodies. A digital mask was created based on GFAP expression. 
Immunofluorescence from GFAP and Lgals3 were segmented with increasing SV values, 
as in other MSV analyses. In this experiment, only Lgals3 expression that colocalized 
with the digital mask was quantified. Lgals3 expression in astrocytes was significantly 
increased after optic nerve crush in both genotypes (Figure 2.9C). Across all 
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segmentation values measured, p < 0.005 in Sncg+/- crushed vs. control and p < 0.05 in 
Sncg-/- crushed vs. control. The mean fold change for Sncg+/- was 2.1 ± 0.02 SEM and the 
mean fold-change for Sncg-/- was 1.7 ± 0.02 SEM.  
These experiments support the idea that Lgals3 might be a general marker of 
reactive astrocytes after injury or degeneration. Lgals3 expression was not affected by 
Sncg in optic nerve crush, but it might be affected after IOP elevation. Reproducing the 
data from lasered Sncg+/- and lasered Sncg-/- with larger sample sizes may show that 
Lgals3 reactivity in hemizygous or knockout Sncg mice is dependent on the type of 
injury inflicted to the optic nerve. It may be that Lgals3 can report physiological changes 
that are specific to glaucomatous degeneration, but the effect is masked during traumatic 
injury. 
 
Discussion 
Sncg is a marker for RGCs, but may not be a causative factor in optic neuropathy 
The expression of Sncg in RGCs has made it a useful marker for labeling RGCs. 
Retrograde labeling can identify RGCs by the injection of tracers directly into the 
superior colliculus or lateral geniculate nucleus [192]. The disadvantage of this technique 
is that it relies upon active transport in order to label the RGC soma. Sncg labeled RGCs 
and axons with similar efficiency as FluoroGold retrograde labeling [10]. It has been 
reproduced here that Sncg identified RGCs in mouse retinas and axons in optic nerves. 
We have only shown Sncg in astrocytes by antibody labeling in optic nerve 
degeneration, but those astrocytes can also express Sncg mRNA after injury (unpublished 
observations). The cytoplasmic distribution of Sncg in astrocytes during degeneration 
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appears to be distinct from the discrete, internalized Sncg structures by astrocytes. The 
widespread, cytoplasmic expression of Sncg in astrocytes was also observed in 
glaucomatous human, rat, and mouse tissue [11; 171]. Sncg has a role in cell proliferation 
[179; 193-195] and astrocyte labeling by Vimentin showed an increase in the number of 
astrocytes in aged D2 [104]. However, the number of astrocytes that expressed Sncg was 
few. The expression of Sncg in astrocytes does not appear to induce proliferation. It is 
unclear what role Sncg may play in astrocyte, or RGCs.   
The expression of Sncg in astrocytes and the formation of Sncg spheroids 
occurred after degeneration. Aberrant expression of Sncg is therefore unlikely to be a 
causative factor in degeneration. But with the new knowledge that astrocytes can 
internalize Sncg spheroids, it may be possible for Sncg to have a pathological effect on 
phagocytic astrocytes. We have not performed an analysis to count the number of Sncg+ 
astrocytes that exist at different stages of degeneration. If Sncg is detrimental to astrocyte 
health, then that may explain the few number of cells found in late degeneration. 
The transfer of synucleins may have a detrimental effect on the receiving cell. 
Lewy bodies containing Snca were found in neuronal grafts in PD-affected patients [196-
198]. Intercellular transfer of Snca was reproduced in cultured neurons, primary neurons, 
and in neuronal grafts in mice [199; 200]. In cultured cells, endogenous cytoplasmic Snca 
surrounded exogenous Snca. This suggested a possible disease mechanism where 
internalized Snca can seed the aggregation of endogenous, cytoplasmic Snca, in a manner 
that might be similar to prions [199].  
Astrocytes can also internalize Snca [201]. In vivo, a mouse that overexpressed 
Snca in neurons had astrocytes with focal Snca accumulation. Interestingly, the authors 
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noted that astrocytes containing Snca were often found alongside myelinated axons. The 
optic nerve is one long myelinated axon tract and the transfer of synucleins may be 
influenced by the integrity of the myelinated axons. The internalization of Snca resulted 
in the increased expression of mRNAs coding for inflammatory cytokines and 
autoimmune responses. The inhibition of lysosomes using bafilomycin A1 prevented the 
degradation of Snca and increased the expression of the cytokines TNFα and CXCL1. 
The internalization of Snca, and by extrapolation Sncg, may result in inflammation that 
causes damage to astrocytes or the surrounding tissue.  
ONH astrocytes are phagocytic in the absence of disease 
Sncg structures were phagocytosed by Lgals3+ astrocytes in D2 [11]. EM showed 
that axonal debris was also phagocytosed by astrocytes throughout a naïve 9-mo-old 
C57Bl/6J ONH [11]. Several genes involved in phagocytic pathways were identified in 
postnatal mouse forebrain [75]. We have shown that the mRNA of Lrp1, Abca1, and 
Mfge8 were expressed in Lgals3+ astrocytes in the optic nerve [11]. Astrocytes appeared 
capable of having an on-going phagocytic role in the optic nerve in vivo.  
Astrocytes express genes involved in different and overlapping phagocytosis 
pathways that are evolutionarily conserved [75; 113]. Megf10 (ortholog of ced-1 in C. 
elegans) expression increased in astrocytes that phagocytosed neuronal material in the 
form of cell corpses [202]. Megf10 and Mertk (a receptor tyrosine kinase that activates 
the CrkII/ced-2 pathway) were involved in astrocytes that phagocytosed synapses [203]. 
Megf10 and Mertk are both receptors that activate pathways that converge onto the Rho-
family GTPase Rac1 [204]. Megf10 and Mertk were shown to work in parallel pathways 
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and it is likely that other redundant phagocytic pathways were also involved in synaptic 
pruning [203].  
In the Glaucoma Discovery Platform database, a transcriptome derived from D2 
ocular tissue, neither Megf10 nor Mertk increased in the ONH when genes were 
organized by morphological phenotype [188-190]. Morphological phenotypes were 
ranked based on severity of optic nerve degeneration, similar to the stages described in 
Results. When organization of gene expression was based on hierarchical clustering, 
Mertk expression increased significantly in the ONH during the second of three early 
stages of disease but decreased by the 3rd stage, and stayed comparable to D2-Gpnmb+ 
transcript levels for the remaining disease stages. Hierarchical clustering grouped 
together tissue with similar gene expression and may be a more sensitive measure of the 
transcriptional changes that occur early in disease. Stages 1-3 were mRNA alterations 
that occurred before detectable nerve damage. The findings of the transcriptome still need 
to be validated in situ, but the absence of significant and continued Megf10 and Mertk 
expression in D2 suggests that an alternative phagocytic pathway is used by ONH 
astrocytes during progressive axon degeneration due to glaucomatous injury. 
The Glaucoma Discovery Platform provides a rich source of material to look for 
new leads or to confirm suspicions of the expression of a particular gene in D2. A search 
for common genes involved in phagocytic pathways identified Mfge8 as one of the few 
genes queried that had significant increased expression by both morphological and 
hierarchical clustering. While morphological clustering is less sensitive at detecting early 
changes in glaucomatous D2 than hierarchical clustering, a consensus between both 
methods may make the gene easier to validate in situ. This is because the morphological 
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stages reported by the database can be matched with the relative amount of axon loss in 
optic nerves. The stages grouped by hierarchical clustering are not easily identifiable 
phenotypically and can lead to uncertainty as to whether the tissue being examined is of 
the proper disease stage for comparison.   
Lgals3 expression provides insight into a novel function of MTZ astrocytes. 
Lgals3 is a galectin, which are a group of proteins that contain a carbohydrate-
recognition domain and bind to β-galactosides [205]. High expression of Lgals3, 
coincident with macrophage markers Mac-1, FcγII/III, and F4/80, was associated with 
active myelin phagocytosis by microglia isolated from C56Bl/6J optic nerve [126]. In 
vivo, microglia in a transected optic nerve had high expression of Mac-1, but variable 
expression of FcγII/III and F4/80. Lgals3 expression was most variable. It was concluded 
that the absence of all four markers expressing highly in in vivo microglia reflected 
deficient activation of microglia. In a different model of injury that mimics multiple 
sclerosis, experimental allergic encephalomyelitis resulted in increased Lgals3 expression 
in phagocytes in the spinal cord and optic nerve during the phagocytosis of myelin [206; 
207]. The differences in Lgals3 expression during demyelination and using two different 
models suggest that its expression is context-dependent.  
The quantification of granular axonal material through SBEM demonstrated that 
debris was distributed throughout the nerve. Sncg may or may not induce Lgals3 
reactivity, but if the internalization of axonal material activated Lgals3 expression then 
Lgals3 would be expected to express in the glial lamina. We observed little expression of 
Lgals3 in the glial lamina. The MTZ located between the glial lamina and fully 
myelinated optic nerve contained the highest relative expression of Lgals3 in each optic 
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nerve [11]. If myelin phagocytosis is a role of Lgals3 that is conserved in astrocytes, this 
suggests that astrocytes in the MTZ might constitutively phagocytose myelin. This would 
explain the lack of Lgals3 expression in the glial lamina. An increase in phagocytic 
activity in the MTZ might also suggest that there is increased debris formation in that 
region. Further work examining the phagocytosis of myelin by astrocytes will be 
described in Chapter 3.  
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Figures 
 
 
Figure 2.1. Sncg mRNA labeled RGCs in mouse retinas. A. 10-mo-old D2-Gpnmb+ 
and age-matched D2 retinas at different stages of RGC degeneration. There was no 
noticeable degeneration in D2-Gpnmb+. There were two sectors of RGC loss (bound by 
black lines) in an intermediate, sectorial stage of degeneration. Higher resolution images 
in white boxes shown in B. In late degeneration, few RGCs remained. B. Sncg mRNA 
labeled RGC somas. An enlarged image of a region with little to no RGC loss (Inset, top) 
and a region within sectorial loss (Inset, bottom) shown. (Scale bars A: 1mm; B: 70µm.) 
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Figure 2.2. Sncg antibody labeled axons, spheroids, and astrocytes in degeneration. 
A. Transverse sections of 10-mo-old D2 optic nerve in different stages of axon 
degeneration labeled with antibodies against Sncg (green) and pNF (red). Asterisks 
indicate regions of axon loss. Bottom panels show enlarged image of glia (white box) 
labeled by Sncg but not pNF. B. Longitudinal ONH sections of same nerves in A, 
showing only Sncg labeling. Asterisks indicate regions of axon loss. Enlarged image of 
region within MTZ (white box) shown to the right of corresponding nerve. C. Transverse 
section of 9-mo-old D2 with sectorial degeneration seen by Sncg (red) and pNF (green). 
D. Longitudinal ONH section of same nerves from C. Some Sncg spheroids were 
contiguous with axons labeled by pNF (arrowhead), while others were detached from 
axons (arrow). (Scale bars A,B: 70µm; C: 50µm; D: 100µm left, 20µm right.)  
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Figure 2.3. Microglial activation in 10-mo-old D2. A. 10-mo-old D2-Gpnmb+ 
contained resident microglia labeled with Iba1 (green) and astrocytes labeled with Lgals3 
(red) in the ONH. Microglia had thickened processes in age-matched D2. Enlarged image 
of microglia (white box) shown below. B. MSV quantification of Iba1 fluorescence in 
D2-Gpnmb+ (solid line) and D2 (dashed line). Shaded region indicates fluorescence 
values where p < 0.005. SV1010 was the segmentation value closest to the mean fold-
change. Errors bars show SEM. C. Transverse sections of D2 optic nerves in different 
stages of disease identified by pNF. Lgals3 and Iba1 colocalized in some cells during 
sectorial and late degeneration. Enlarged view of cells (arrow) shown to the right. (Scale 
bars A,C: 70µm.) 
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Figure 2.4. Antibody against Sncgaa108-123 selectively labeled glia in diseased retina 
after PK treatment. A. 661W cells transfected with plasmids expressing GFP fused to 
full-length mouse Sncg (GFP-Sncg) or C-terminal truncated Sncg (GFP-SncgΔC). GFP 
antibody identified transfected cells. Sncgaa21-127 and Sncgaa108-123 antibodies labeled cells 
transfected with full-length Sncg, but Sncgaa108-123 antibody did not detect truncated Sncg. 
B. Sncgaa108-123 antibody had reactivity in diseased D2 retina after PK treatment. Sncgaa21-
127 (green) and Sncgaa108-123 (red) antibodies both labeled RGCs and axons in the NFL in 
3-mo-old D2 before PK. Degeneration in 10-mo-old retina showed absence of RGC and 
axon labeling, but revealed glial labeling. After PK treatment, there was no specific 
labeling in young retinas but the glial labeling in the IPL (brackets) by Sncgaa108-123 
remained. (Scale bars A: 20µm; B: 50µm.) 
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Figure 2.5. Lgals3 expressed in optic nerve astrocytes. A. Lgals3 (green) expressed in 
astrocytes identified by GFAP (red) in 3-wk-old C57Bl/6J ONH. B. Lgals3 (red) labeled 
astrocytes identified by GFP (green) and GFAP (blue) expression in transverse sections 
of 1-mo-old mice expressing GFP under the astrocyte promoter GLT1. (Scale bars A,B: 
70µm.)  
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Figure 2.6. Lgals3 expression highest in MTZ within the ONH. A. The peak of Lgals3 
(red) expression coincides with the onset of myelination (Myelin basic protein, green). B. 
MSV quantification of Lgals3 expression from two different cohorts of 10-mo-old D2-
Gpnmb+ (solid line) and D2 (dashed line). Shaded region indicates fluorescence values 
where p < 0.005. SV400 (top graph) and SV370 (bottom graph) were the segmentation 
values closest to the mean fold-change of each experiment. Errors bars show SEM. C. 
Same ONHs as Figure 2.2.B. Lgals3 expression is highest at MTZ within an individual 
nerve. There was greater overall Lgals3 expression with axonal degeneration. (Scale bars 
A,C: 70µm.)  
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Figure 2.7. Sncg structures were close to and within Lgals3+ astrocytes in mouse 
glaucoma models. A, B. Confocal microscopy of MTZ astrocytes labeled with Lgals3. 
A. Arrowheads indicate Sncg structures found in young and old D2. Cell labeled by 
arrow shown in bottom row of images. B. Sncg structures were internalized within 1 day 
of IOP elevation by translimbal laser photocoagulation. MTZ astrocytes express both 
Lgals3 mRNA (white) and protein (green). Sncg labeled structures (red) were completely 
surrounded by Lgals3 protein in the cytoplasm. (Scale bars A,B: 5µm.)  
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Figure 2.8. Axon debris found in the ONH in the absence of degeneration. A. SBEM 
of 9-mo-old C57Bl/6J ONH showed granular accumulations in protrusions (white 
arrows) that were still attached to an axon (left) in the glial lamina and MTZ. Evulsions 
were debris with a similar appearance to protrusions but disconnected from an axon 
(center, black arrows). Evulsions were contained by a membrane after being internalized 
by an astrocyte. Loss of the evulsion membrane and presence of granular material in the 
astrocyte cytoplasm suggested degradation of the evulsion membrane (right). (Scale bar 
A: 1µm.)  
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Figure 2.9. Lgals3 expression in Sncg+/- or Sncg-/- mouse ONH after injury models. 
A. MSV quantification showed an increase of Lgals3 in Sncg+/- 7 days after IOP 
elevation. B. Lgals3 increased in GFAP+ astrocytes by approximately 2-fold in all 
segmentation values after optic nerve crush. C. Lgals3 (green) and GFAP (red) 
expression in ONH after optic nerve crush in Sncg+/-. Asterisk is anterior to crush site. 
Enlarged image of amoeboid cells (white box) found near the crush site were GFAP- and 
Lgals3+ (arrows) shown below. (Scale bars C: 70µm.) 
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Chapter 3: The continued phagocytosis of myelin 
by astrocytes leads to the formation of lipid 
droplets 
 
Preface 
Chapter 3 contains data regarding the internalization of myelin by astrocytes and the 
subsequent formation of lipid droplets in astrocytes (manuscript in progress). 
 
Figures 3.2 and 3.3A, B were performed by Keun-young Kim and Eric Bushong.  
Figure 3.2D tracing and 3D modeling were generated by Akshay Murthy. 
Figure 3.5A was performed by Chung-ha Davis.  
All other work was original data generated by JVN under the supervision of Nicholas 
Marsh-Armstrong. 
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Introduction 
Myelination is important for the rapid conduction of action potentials along the 
length of an axon. The loss of myelin integrity can result in motor impairments, loss of 
sensation, and vision loss in demyelinating diseases such as multiple sclerosis. There are 
many factors involved in maintaining the integrity of action potential transmittance and 
the stability of the myelin sheaths.  
 Ion channels, namely sodium channels in the nodes of Ranvier and potassium 
channels in the juxtaparanode, are important for depolarization and repolarization of the 
axon membrane potential. In the rat optic nerve, the sodium channel subunit Nav1.2 was 
expressed on axons during developmental myelination and Nav1.6 was concentrated at 
the nodes of Ranvier in the myelinated nerve [208]. In a mouse model of experimental 
allergic encephalomyelitis (EAE), there was a shift in the type of sodium channel 
expressed, as well as a disruption in the expression of the axonal paranode protein Caspr 
in optic nerves [209]. Nav1.2 was expressed in the majority of Caspr-labeled nodes 
instead of Nav1.6. While Caspr and the sodium channels generally localized to the 
paranode and node properly, expression was diffuse and less sharply defined than in 
control tissue. The demyelination caused by EAE can affect the neuron by allowing 
diffuse localization of sodium channels at the nodes of Ranvier which may impair 
saltatory conduction.  
Sodium channels have been proposed as a molecular target in neurodegenerative 
diseases because of their influence on axon health as well as nerve function [210-213]. 
Axon degeneration can occur independently of defects in myelination when the 
dysfunction of sodium channels causes a reversal in the activity of the sodium/calcium 
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exchanger [214-216]. Excess calcium that flows into the neuron causes excitotoxicity and 
blocking calcium channels can be therapeutic [217]. The utilization of sodium channel 
blockers is under examination for the treatment of multiple sclerosis [218-220]. 
The paranodal region of myelinated axons are also of interest in the study of 
neurodegeneration. Myelin-associated glycoprotein (MAG) is a sialoadhesin protein 
[221] that is expressed in the periaxonal space and enriched in the paranodal loops of 
myelin that make contact with an axon at the boundaries of the nodes of Ranvier [222; 
223]. MAG can inhibit neurite outgrowth through interactions with gangliosides on 
axonal membranes [224] and this is proposed to be a factor that inhibits axon 
regeneration in the central nervous system (CNS) after injury [225; 226]. Defects in 
MAG or ganglioside expression can destabilize the paranodes, and the loss of both MAG 
and a key enzyme in glycosphingolipid synthesis, UDP-galactose ceramide 
galactosyltransferase, led to accelerated breakdown of axo-glial interactions [227-230]. 
The regions that surround the nodes of Ranvier can impact the health of the axon and 
myelin. 
Multiple astrocyte processes can make direct contact with axons at nodes [89] to 
influence neuronal health and function. Astrocytes remove ions like potassium [231] or 
excitatory neurotransmitters like glutamate [90; 232; 233] from the synapse. Axons in the 
optic nerve were observed to release glutamate as well [234], in the form of ectopic 
vesicles after laser-induced intraocular pressure (IOP) elevation [59]. Astrocytes also 
influence the formation of functional synapses through the secretion of cholesterol [235-
237].  
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The myelination transition zone (MTZ) of the ONH was shown to be a region 
containing a distinct population of astrocytes that express Lgals3 [11]. The onset of 
myelination results in the presence of heminodes, which are only found at regions where 
myelination would begin or end. Astrocytes expressing Lgals3 may therefore be reactive 
against something specific to heminodes. Axons in the glial lamina express Nav1.2 [208], 
even in adults, and the differences in sodium channel distribution or node biology as the 
optic nerve transitions from unmyelinated to myelinated might affect Lgals3 reactivity. I 
propose that the myelin at the MTZ is inherently unstable due to factors that regulate 
myelination onset and because of this instability, the MTZ is more likely to form myelin 
debris. Phagocytic astrocytes can remove extraneous myelin without activating 
inflammatory pathways that might lead to macrophage infiltration and would explain the 
presence of Lgals3-expressing astrocytes at the MTZ. The work described in this chapter 
has led to the identification of structural and molecular evidence that astrocytes do indeed 
perform such a function as clearing myelin.  
 
Results 
Myelin alterations in the D2 optic nerve 
The MTZ is the focus of our in vivo studies due to the identification of a 
subpopulation of astrocytes that express Lgals3 [11]. Myelin in the MTZ was examined 
immunohistochemically for structural features that might suggest instability of myelin 
sheaths. The QD-9 Myelin Basic Protein (MBP) antibody (hereafter referred to as QD-9) 
recognizes the conserved epitope QDENPVV and is found at positions amino acids (aa) 
108-114 in isoform 1 and isoform 2; aa 82-88 in isoform 3 and 4; aa 215-221 in Golli-
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MBP isoform 1; and is absent in Golli-MBP isoform 2. QD-9 had specific reactivity in 
Multiple Systems Atrophy brain samples, but little reactivity in normal brain [238; 239]. 
This antibody was also more sensitive than Luxol fast blue staining at reporting myelin 
damage in a rat ischemic model [240]. The QD-9 epitope may be a significant factor in 
the autoimmune response in multiple sclerosis [241; 242]. QD-9 may indicate disruptions 
in the myelin sheath that lead to exposure of the epitope on MBP.  
The ONH from a control 3-mo-old Balb/C mouse ONH was labeled with QD-9 
and an MBP antibody not known to have any preference for intact or degenerating 
myelin. There was only weak staining of QD-9 (data not shown). However, there was 
colocalization of both antibodies in 10-mo-old DBA/2J (D2), a mouse glaucoma model, 
and DBA/2J-Gpnmb+/Sj (D2-Gpnmb+) ONH, the control strain for D2 (data not shown). 
It was not tested whether QD-9 would label myelin in other strains of mice that were 10-
mos-old or if 3-mo-old D2 would have QD-9 reactivity. There appeared to be specificity 
towards myelin sheaths because QD-9 labeling always excluded axons within the glial 
lamina.  
The ONHs of 10-mo-old D2 and D2-Gpnmb+ ONH were examined with QD-9. 
The brightest QD-9 signal in D2 came from small objects between myelinated axons 
(Figure 3.1A). These QD-9 reactive objects were found primarily in the MTZ of both 
genotypes and appeared to be punctate as well as projecting in a direction different from 
the long axis of the myelin sheaths. The QD-9 puncta and projections were more 
abundant and more strongly labeled in D2. The fluorescence intensity of QD-9 was 
quantified using multiple segmentation values (MSV) to estimate fold-change in D2. 
MSV provide measures of signal intensity across multiple fluorescence thresholds. The 
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D2 fluorescence intensities differed from the D2-Gpnmb+ values at a significance level of 
p ≤ 0.005 (two-tailed, unpaired t-test with Welch’s correction) over a range of 
segmentation values (SV) (Figure 3.1B). The mean fold-change was 2.2 (SEM 1.1).  
SV450 was closest to the mean fold-change and had values of x̄  = 23.4 (SEM 3.1) in D2-
Gpnmb+ mice (N = 8, x̄ sections quantified = 5) and x̄  = 53.2 (SEM 4.6) in D2 mice (N = 
6, x̄ sections quantified = 5). The quantified increase in fluorescence intensity of QD-9 
was consistent with the observation of increased fluorescence, but is paradoxical in light 
of the known loss of both axons and downregulation of oligodendrocyte markers that 
occur in this animal model [104]. Therefore, an alternate method of quantifying myelin 
was used. Individual 3mm long segments of ONH from 12-mo-old D2-Gpnmb+ and D2 
mice were analyzed by western blot. There was half as much protein detected using MBP 
antibody in D2 than in D2-Gpnmb+ (D2-Gpnmb+ x̄  = 0.6, SEM 0.1, N = 5; D2 x̄  = 1.2, 
SEM 0.1, N = 9) (Figure 3.1C, D). 
D2 are known to have asynchronous disease development with RGC degeneration 
occurring focally before spreading in a sectorial fashion, followed by widespread loss [9; 
10; 12; 24; 27]. The severity of disease was examined for each of the D2 cohorts to 
determine whether a difference in disease severity might account for the increase of QD-
9 immunoreactivity and decrease of MBP protein by western blot. The degree of 
degeneration was determined by axon labeling of transverse sections. Nerves without 
axon loss had axons that were evenly distributed and of a dense concentration. These 
were scored as no noticeable degeneration (NND). Regional loss of axons up to 60% 
were scored as sectorial. The loss of more than 60% of axons was scored as degenerated. 
The D2 cohort used for immunofluorescence contained 1 nerve with NND, 5 nerves with 
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sectorial degeneration, and 1 nerve that was degenerated. The D2 cohort used for western 
blot contained 1 nerve with NND, 1 nerve with sectorial degeneration, and 7 nerves that 
were degenerated. All D2-Gpnmb+ had NND. Because the cohorts were mismatched in 
terms of disease severity, it is unclear whether increased QD-9 antigenicity accompanied 
loss of MBP. The QD-9 reactivity may be reporting myelin undergoing degeneration with 
the QD-9 epitope exposed or nascent myelin sheaths that were not fully compacted and 
thus had the QD-9 epitope exposed.  
Myelin debris in the MTZ by SBEM 
The bright puncta labeled by QD-9 were found in both D2 and D2-Gpnmb+, 
indicating that the cause for this reactivity occurred in non-diseased and diseased 
conditions. The appearance of the QD-9 puncta and protrusions indicated that the myelin 
sheaths may have irregular morphology. A non-degenerated C57BL/6J ONH that was a 
previously reported [11] was re-examined for myelin irregularities. The most osmiophilic 
material in the optic nerve is typically myelin, due to the abundance of lipids within the 
membranes. Normal myelin sheaths are compact, and the concentric sheaths are often 
visible by the appearance of major dense lines and intraperiod lines. Myelinating sheaths 
are found tightly surrounding electron-lucent axons. Other structures visible by electron 
microscopy include organelles and vesicles that are present within the axons or in the 
surrounding glia. In these micrographs obtained from serial block-face scanning electron 
microscopy (SBEM), there were multiple myelin bodies found. 
The myelin irregularities observed in the C57Bl/6J ONH included a large granular 
structure within a glial cell that contained components that appeared similar to detached 
myelin (Figure 3.2A). These detached myelin figures had concentric rings of osmiophilic 
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material. A second irregularity was a myelinated axon that folded back upon itself 
(Figure 3.2B). An oblique cutting plane resulted in the appearance of two separate axons. 
A third irregular myelin structure was a myelin protrusion detached from an otherwise 
intact myelin segment (Figure 3.2C). The myelin protrusion was traced through serial 
sections and found to stretch over a distance of 6 µm. There was little axonal cytoplasm 
in this myelin structure as it terminated inside a glial process. A three-dimensional (3D) 
reconstruction of this myelin sheath, as well as other nearby myelin sheaths, revealed 
multiple myelin protrusions from three different myelin segments (Figure 3.2D). Two 
long protrusions were inside of the same glial process. This cell was provisionally 
identified as an astrocyte through the radial arrangement of its processes and contact with 
a blood vessel. There were many myelin irregularities found in a 9-mo-old C57Bl/6J 
ONH and some of those irregularities were closely associated with astrocytes.  
Based on the similarity of size and localization within the MTZ, it seemed that the 
bright puncta and protrusions detected by QD-9 in the MTZ represented some 
combination of the large irregular myelin bodies that were completely detached from 
axons and the thin, long myelin protrusions that were continuous with existing myelin 
segments. The combination of immunofluorescence, western blotting, and SBEM data 
suggests that myelin debris forms in naïve ONH and that astrocytes in the MTZ actively 
internalize and degrade myelin. 
Electron-dense spherical structures are likely lipid droplets in the D2 ONH 
Because D2 optic nerves were shown to have increased QD-9 puncta and 
protrusions and overall decreased myelination, D2 optic nerves were expected to show 
increased signs of myelin instability. SBEM data was then collected from 9-mo-old 
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ONHs of D2-Gpnmb+, D2 without obvious signs of axon loss (mild), and D2 with severe 
degeneration (severe). Subvolumes selected from regions of the glial lamina and MTZ 
were extracted and examined for signs of myelin irregularities. As previously seen in 
C57Bl/6J [11], there were granule accumulations and osmiophilic structures throughout 
each ONH (Figure 3.3A). The absence of identifiable markings, such as the cristae of 
mitochondria or period lines of myelin, suggested that many osmiophilic structures were 
membranous debris. Compact myelin was also observed as a myelin body that did not 
contain an axon within the sheath. The myelin irregularities identified in D2 and D2-
Gpnmb+ were consistent with what was observed in C57Bl/6 ONH. 
The MTZ of D2 (mild) nerve had a unique feature not seen in D2-Gpnmb+ or D2 
(severe). There were gradients of electron density throughout the volume of data that 
corresponded to glial processes but did not spread to the cell body. These cells appeared 
unremarkable in other aspects of cell morphology. The significance of these electron-
dense processes is undetermined.  
Numerous electron-dense spherical objects were also present in the nerves, most 
visibly in the mildly diseased D2 MTZ. These spherical objects varied in size from 
approximately 10nm to 15µm in diameter and were located primarily within glial cell 
bodies. These structures had high electron density around its perimeter, which allowed 
the use of minimum intensity projections to display their distribution and frequency 
(Figure 3.3B). An automated quantification of these spherical objects (Experimental 
Materials and Methods) revealed that the mildly diseased D2 indeed contained more 
objects in the MTZ than in the lamina (Figure 3.3C). The volumes of the objects were 
similar across all subvolumes and the only statistically significant comparison was 
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between the MTZ of D2-Gpnmb+ and MTZ of D2 (mild) (1-way ANOVA with Tukey’s 
comparison, p < 0.05) (Figure 3.3D). The largest objects were found in D2 (mild) MTZ.  
The regular, spherical morphology of the electron-dense structures suggested that 
they might be lysosomes, peroxisomes, or lipid droplets. Preliminary studies examined 
the lysosomal proteins cathepsin K, cathepsin D, LAMP1, and LAMP2 by 
immunofluorescence in D2 ONH to look for specific expression in the MTZ. There was 
little labeling of the cathepsins and some labeling by LAMPs (data not shown). LAMP1 
was found throughout the ONH. LAMP2 appeared to have a slight specificity for the 
MTZ compared to the glial lamina or distally in the nerve, but did not appear to be 
specific to a particular cell type. Peroxisomal proteins were also examined (data not 
shown). Antibodies against PMP70 and Pex14 were screened in D2 ONH and showed no 
specific reactivity, and catalase appeared diffuse and punctate throughout the ONH (data 
not shown). 
Lipid droplets form after traumatic injury in microglia and macrophages, and 
were infrequently observed in astrocytes of the rat optic nerve [243]. Lipid droplets store 
excess lipids, and these may be derived from the membranes of axons and myelin. Early 
in neurodegeneration, there may be increasing amounts of myelin debris that is 
phagocytosed by astrocytes without macrophage infiltration. Increasing amounts of 
myelin internalization may explain the abundance of putative lipid droplets quantified in 
the MTZs of ONHs.  
Cultured astrocytes phagocytose myelin 
We next set out to establish a model system to study the phagocytosis of myelin 
by astrocytes and address the formation of lipid droplets as a result of myelin 
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internalization. A model system was formed by isolating primary astrocytes from mouse 
cerebral cortex and feeding the cells myelin extracted from bovine optic nerves. An MBP 
antibody was applied to fixed cells before membrane permeabilization in order to identify 
myelin that was not internalized. MBP antibody was applied again after treatment with 
detergent and labeled with a different fluorescent secondary antibody to label the 
remaining myelin. MBP antibody detected large and small myelin structures, some of 
which were only labeled after membrane permeabilization (Figure 3.4A). MBP was 
localized to astrocytes that expressed GFAP and Lgals3 (data not shown), but Lgals3 
expression was not predictive of MBP internalization. Astrocytes expressed varying 
intensities of GFAP, and not all cells that expressed GFAP also expressed Lgals3 (data 
not shown).  
Astrocytes were exposed to myelin for 1 hour (hr) to determine whether 
astrocytes could degrade acute loads of myelin. Samples of astrocytes were collected 
before myelin addition, at wash out (1 hr post feed, p.f.), and at 24 hrs p.f. By 24 hrs, 
internalized myelin signal decreased by approximately 68% and external myelin was not 
detected (Figure 3.4B). These results suggested that astrocytes were able to internalize 
and degrade myelin.  
The time of myelin exposure to astrocytes was increased to 24 hrs to determine 
whether extended myelin internalization would have an effect on degradation. Under 
these conditions, the amount of myelin within astrocytes remained constant even after 2 
days with no additional myelin feeding (Figure 3.4C). MBP outside the cells was 
significantly decreased, suggesting some degradation occurred. To see whether other 
myelin markers would report the same results, we repeated the experiments and analyzed 
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a second myelin marker, Galactocerebroside (GalC). The findings with GalC were 
similar to those with MBP. Astrocytes internalized myelin, but were unable to efficiently 
degrade it. The prolonged period of myelin internalization may have saturated the 
mechanisms used to internalize and degrade myelin.  
Surprisingly, the amount of GalC outside the cell decreased more slowly over the 
course of 2 days than MBP. The amount of GalC outside of astrocytes by the 3rd day was 
49% of what it had at the end of the feeding period. This was in contrast to MBP, which 
had 15% left at Day 3. Astrocytes might be able to internalize proteins like MBP more 
effectively than complex lipids like GalC or there may be extracellular proteases, but not 
lipases, that were secreted by astrocytes. These factors might explain the preferential 
reduction of MBP signal.  
The internalization of myelin may have had a toxic effect on the astrocytes. To 
examine astrocyte viability, 3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium 
Bromide (MTT) assay was performed. Three different concentrations of myelin feeding 
(0.5X, 1X, and 2X proportional amounts of myelin used in immunofluorescence) were 
fed to astrocytes for 24 hours and time points were taken over the next 5 days. There was 
no effect on astrocyte viability as determined by the reduction MTT (data not shown). 
Cultured astrocytes repeatedly fed myelin develop lipid droplets 
After cultured astrocytes were determined to be able to internalize and degrade 
myelin, we tested whether cultured astrocytes would develop lipid droplets similar to 
those observed by SBEM in early glaucomatous degeneration. Transmission electron 
microscopy (TEM) revealed electron-dense, irregularly-shaped structures, presumably 
myelin debris, inside cultured astrocytes after 24 hrs of myelin feeding (Figure 3.5A). 
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Oleic acid is known to induce lipid droplet formation in various cell types, though this 
has not been studied in astrocytes specifically [244; 245]. Cultured astrocytes were 
incubated in 300µM oleic acid for 3 days. This regimen induced the formation of large 
spherical structures with electron-lucent cores and an irregular electron-density around its 
perimeter. There were also small spherical, irregularly-dense objects. The abundance of 
large lipid droplets after oleic acid exposure suggested that these are more comparable to 
prototypical lipid droplets, while the smaller lipid droplets may represent a nascent or 
intermediate lipid droplet form.  
There were few lipid droplet-like structures in astrocytes fed myelin for 1 day, so 
an additional regimen of continuous and repeated myelin feeding was developed. Myelin 
was fed once a day for 3 days, with fresh myelin replacing old myelin. Astrocytes under 
these conditions formed the larger spherical structures with electron-lucent cores and the 
smaller spherical, electron-dense structures that were also seen after oleic acid 
incubation. These results of these experiments demonstrate that repeated and prolonged 
myelin exposure can lead to the formation of lipid droplets in cultured astrocytes.  
ORO and Plin2 label lipid droplets in myelin-fed astrocytes 
To quantify the lipid droplet response by astrocytes after myelin feeding, cultured 
astrocytes were labeled with Oil Red O (ORO). ORO is a lipophilic dye commonly used 
to label neutral lipids such as triacylglycerols and cholesteryl esters [246]. These lipids 
constitute the hydrophobic core of lipid droplets. The intrinsic red fluorescence of ORO 
was quantified in astrocytes that were continuously and repeatedly fed myelin once a day 
for 3 days. This regimen of myelin feeding produced an increase in ORO staining, which 
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was comparable to the amount induced when cells were incubated with 100µM oleic acid 
(Figure 3.6A).  
Myelin-fed astrocytes were also examined for the expression of a lipid droplet 
protein to further validate the appearance of lipid droplets after myelin feeding. Plin2 
associates with the membranes of lipid droplets and is expressed in more diverse cell 
types than other proteins in the perilipin family [247; 248]. Plin2 is rapidly degraded in 
the absence of lipid droplets [249] and therefore may be a reliable marker for lipid 
droplet presence. In cultured astrocytes, Plin2 immunofluorescence was near background 
levels of fluorescence (personal observations). Myelin-fed and 100µM oleic acid-fed 
cells both showed comparable induction of ring-shaped Plin2 structures at the end of the 
3 day feeding schedule (Figure 3.6B).  
With Plin2 as a protein reporter for lipid droplet formation in cultured astrocytes, 
western blotting was used to re-examine the conditions of myelin feeding that could lead 
to lipid droplet formation. The first condition considered was whether there was a dose-
dependent increase in Plin2 with myelin feeding. Similar to the experiment by TEM 
where lipid droplets were induced by myelin feeding, astrocytes were continuously and 
repeatedly fed myelin every day for 3 days. In this experiment, cells were lysed daily to 
monitor the progression of lipid droplet formation. Plin2 increased after each day of 
myelin feeding, but only reached a statistically significant increase after the 3rd day of 
feeding (Figure 3.7A). In the same western blot membranes, total MBP increased with 
repeated feedings. Plin2 and MBP both increased over the course of the feedings and may 
indicate that the astrocytes form lipid droplets when MBP is not efficiently degraded. 
68 
 
The feeding regimen of 24 hrs of myelin exposure was re-examined and time 
points were taken every day following myelin wash out. Plin2 expression was unchanged 
and MBP showed a progressive decrease over the 3 day time course (Figure 3.7B). The 
lack of Plin2 induction was mostly likely because the myelin was efficiently degraded 
and not accumulated. Cultured astrocytes were fed myelin for 1 hr and time points were 
taken within the next 24 hrs. Plin2 expression did not change in the time points measured 
subsequent to washout (Figure 3.7C). To consider the impact of brief but repeated 
myelin feeding, cultured astrocytes were fed for 1 hr per day for 3 days. Plin2 showed no 
significant increase at the end of 3 days (unfed cells x̄ = 0.1 (SD 1.1); fed cells x̄ = 0.3 
(SD 1.1); N = 3, unpaired two-tailed t-test, p = 0.2). In these conditions where MBP was 
reduced by the end of the time course, there was no significant increase in Plin2 
expression. 
Myelin was degraded by astrocytes, but the efficiency was reduced when the 
exposure to myelin was extended from 1 hr to 24 hrs. When myelin was accumulated 
after repeated and continuous myelin feeding, the astrocytes formed lipid droplets. Lipid 
droplet formation was seen by TEM, ORO staining, Plin2 immunofluorescence, and 
Plin2 immunoreactivity by western blotting. Plin2 expression was consistent with the 
formation of lipid droplets in astrocytes. The break down or liberation of lipids is a 
prerequisite for the formation of lipid droplets, suggesting that myelin degradation still 
occurred even if overall MBP levels did not decrease. The cellular machinery used to 
break down myelin appeared to be overwhelmed by the increased myelin load. Lipid 
droplets formed when the astrocytes could not efficiently degrade myelin. 
Plin2 increases in ONH astrocytes in mouse glaucoma models 
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Because Plin2 appeared to report lipid droplet formation, we quantified Plin2 
expression in D2 ONHs to corroborate the putative lipid droplets identified in D2 ONH 
by SBEM. Western blotting was used first to determine whether there was increased 
Plin2 expression in 10-mo-old D2 and D2-Gpnmb+ ONHs. Plin2 increased by 3.8-fold in 
the ONH of D2 mice (x̄  = 4.1, SEM 0.6, N = 9) compared to control ONH (D2-Gpnmb+ 
x̄  = 1.1 SEM 0.1, N = 5) (Figure 3.8A top, B left).  
The expression of Lgals3 was also examined because we hypothesized that 
Lgals3 was reactive in response to phagocytic activity by the astrocytes. Lgals3 increased 
by 3.6-fold (D2-Gpnmb+ x̄  = 1.0, SEM 0.1, N = 5; D2 x̄  = 3.7, SEM 0.8, N = 9) (Figure 
3.8A bottom, B right). Previous quantifications of Lgals3 by immunofluorescence using 
MSV provided a wide range of fold-change in D2 [11]. Quantification of Lgals3 protein 
in western blot here provided an additional measure of expression. Most measures of 
Lgals3 in D2 [11; 188-190] calculated a 2 to 4-fold increase in D2 over D2-Gpnmb+ by 
immunofluorescence and messenger RNA (mRNA) microarray. One MSV quantification 
out of 3 resulted in a 25-fold increase in Lgals3 (Chapter 2). That quantification may be 
an overestimate due to anomalies in quantification of that dataset or insufficient sample 
of D2 phenotypes. 
It was necessary to return to imaging methods to determine what cell type 
expressed Plin2. First we determined whether Plin2 was increased in the D2 cohort to be 
used for analysis. A significant Plin2 increase was seen over a range of segmentation 
values (p < 0.001 using unpaired t-test with Welch’s correction), with the mean fold-
change of 5.8 (SEM 0.2) (Figure 3.8C). SV410 contains values closest to this mean 
where D2-Gpnmb+ x̄  = 0.17 (SEM 0.03, N = 11) and D2 x̄  = 0.99 (SEM 0.17, N = 13). 
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Plin2 was also quantified in a second mouse model of glaucoma using MSV. This model 
induced elevated IOP after translimbal laser photocoagulation in an experiment that was 
previously reported [11]. There was a 10.3 (SEM 0.8) mean fold-change of Plin2 in ONH 
from lasered eyes versus unlasered eyes (Figure 3.8D). At SV350, the mean of untreated 
eyes was 0.2 (SEM 0.1, N = 7) and of lasered eyes was 2.4 (SEM 0.6, N = 11).  
Then, we were able to determine in which cell type Plin2 upregulation occurred. 
Plin2 immunoreactivity was analyzed with respect to markers that identify the MTZ 
astrocytes (Lgals3) and microglia (Iba1) using images taken from the D2 nerves 
quantified in Figure 3.8D. Although Lgals3 also expressed in some microglia, the 
majority of Lgals3 signal in the MTZ was in GFAP+ astrocytes [11]. An image mask of 
either Lgals3 or Iba1 expression was created and the Plin2 expression within each mask 
was quantified. MSV were used for each gene, with Plin2 signal normalized by each 
progressively smaller mask area (Figure 3.9B). Higher segmentation of Plin2 represents 
more stringent conditions for the detection of Plin2 signal and a positive slope indicates 
co-localization. Plin2 after translimbal laser photocoagulation was also increased in 
Lgals3-expressing astrocytes (data not shown). The quantifications were in agreement 
with the images obtained from the dataset that qualitatively showed the majority of Plin2 
signal within Lgals3 expression (Figure 3.9A). The results show that astrocytes form 
lipid droplets during glaucomatous degeneration.  
 
Discussion 
Myelin instability in the MTZ 
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The MTZ had myelin irregularities seen by reactivity to QD-9 and 
ultrastructurally by SBEM. These observations suggest that myelin in the MTZ inherently 
forms more myelin protrusions and myelin bodies as compared with regions more distal 
to the ONH. This could be interpreted as increased myelin turnover and may be due to 
damage from daily stress or age, but appeared to be a normal biological process. Myelin 
turnover mostly likely does not result in a net loss of myelin because new myelin 
segments can be generated by adult-born oligodendrocytes that intercalate with existing 
sheaths [250]. EM of adult rat MTZ, or the retina-optic nerve junction as it was called, 
observed both axon and myelin protrusions at heminodes [18]. Heminodes contain one 
paranode and juxtaparanode region, as compared to paired regions in a full node of 
Ranvier. Node length and internode length were of varying lengths in the MTZ and some 
paranodal loops were only partially attached or faced in the opposite direction of its axon. 
It was suggested that the axo-glial interactions appeared to be immature or to have 
prematurely arrested development. The results described here would support the idea that 
myelin or heminode architecture in the MTZ may appear immature, but I propose that it 
is not due to arrested development, but is instead due to constant remodeling through the 
phagocytic activity of astrocytes.  
In multiple sclerosis, optic neuritis causes demyelination but does not necessary 
lead directly to axon loss. Treating the inflammation caused by optic neuritis with 
steroids can improve vision temporarily, but vision is unlikely to be completely restored 
without full remyelination [251; 252]. Animal models that induce focal demyelination in 
the optic nerve do not typically show remyelination [253; 254]. One study examined the 
effects of irradiated food on cats and found extensive demyelination with accompanying 
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motor defects [255]. After the irradiated food was withdrawn, axons in the spinal cord 
and optic nerve had thin myelin sheaths which indicated that remyelination had occurred. 
This work demonstrated that remyelination was possible, but the mechanism or 
circumstances required are unknown. If there is constant myelin turnover and 
remyelination in the MTZ, then it may be a novel model to study the stability of 
myelination, dysmyelination, and integrity of nodes of Ranvier without added 
complications from using a disease model.  
Phagocytic activity of astrocytes 
We previously reported microglial and astrocyte expression of Lgals3 in the 
myelinated optic nerve [11; 104] but expression was especially strong in astrocytes of the 
MTZ [11]. There was also a reported increase in transcriptional expression of Lgals3 in 
all stages of D2 disease examined [188-190]. Cultured astrocytes that did not express 
Lgals3 still had internalized myelin. This may be due to the activation of a phagocytic 
pathway that is independent of Lgals3 or because the culture system permitted activity 
that would not be typically seen in vivo.  
We observed cultured astrocytes fed myelin containing no MPB 
immunoreactivity and other cells that had numerous bodies of MBP immunoreactivity. 
The variance in phagocytic activity of cultured astrocytes was also observed in a model 
where astrocytes phagocytosed apoptotic neurons [202]. These results suggest that the 
phagocytic ability of astrocytes may be limited to a subpopulation of astrocytes. This is 
consistent with the idea that MTZ astrocytes expressing Lgals3 are involved in myelin 
phagocytosis. Cultured astrocytes that do not express Lgals3 but still internalize myelin 
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may reflect an inherent ability of astrocytes. The difference in in vitro versus in vivo 
context may explain the variable expression of Lgals3 in culture.  
It was also reported that an acidic pH-sensitive fluorescent marker was not 
activated in astrocytes with internalized nuclei within 3 days, yet macrophages contained 
fluorescence within 5 hrs [202]. This result indicated that macrophages use lysosomes to 
degrade neuronal nuclei, but astrocytes did not use lysosomes nor did they degrade nuclei 
within the time frame observed. My own experiments with lysosomal proteins LAMP1, 
LAMP2, and cathepsin D showed no reproducible colocalization with internalized 
myelin.  
Immunofluorescence demonstrated that myelin was stored in the astrocyte 
cytoplasm when the exposure to myelin was extended from 1 hr to 24 hrs. However, 
MBP was decreased by western blot using the same time course. MBP by 
immunofluorescence was normalized by Day 1 values while MBP in western blotting 
was normalized to actin. The amount of internalized myelin may have been small 
compared to the total amount of myelin added to the culture. Western blot may not be 
sensitive enough to detect this amount. Imaging techniques are useful for studying subtle 
changes or to localize genes of interest within a certain cellular compartment or region, 
but analysis is limited to the area imaged. Western blots require larger changes in protein 
expression to be detectable, but may better reflect the tissue as a whole. The 
complementary nature of these two methods should be considered when examining subtle 
biology. 
Myelin was accumulated by western blot in the continuous and repeated myelin 
feeding experiment and this was the only condition to produce Plin2 expression. Shorter 
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exposures did not lead to Plin2 expression. We reasoned that the cellular machinery used 
to metabolize myelin proteins and lipids became overwhelmed with the increased myelin 
load. The inability to degrade internalized material may eventually result in negative 
consequences to the astrocyte. MTT assay did not show differences in the viability of 
astrocytes fed myelin but the long-term consequences on viability or cell biology were 
not examined.  
Optic nerve astrocytes are not the only non-professional phagocyte in the visual 
system. Retinal pigmented epithelial (RPE) cells actively phagocytose the outer segments 
of photoreceptors in the retina [256]. In age-related macular degeneration, RPE cells 
accumulate non-degradable remnants called lipofuscin [257; 258]. The accumulation of 
lipofuscin in cultured retinal pigment epithelial cells was observed to inhibit further 
phagocytosis [259] and could possibly have other negative effects on the health of the 
outer retina [260; 261]. In the absence of dysfunction, RPE cells form retinyl-ester 
containing lipid droplets called retinosomes. Lipofuscin is distinct from retinosomes 
[262; 263]. Retinosomes have a place in the normal biology of RPE cells by facilitating 
the recycling of 11-cis-retinal, which is a chromophore used by photoreceptors to capture 
photons [263]. Similar to RPE cells and retinosome formation, astrocytes in the ONH 
were also shown to be phagocytic and form lipid droplets.  
Significance of lipid droplets in the ONH 
Cells containing excess lipids typically esterify and store them in lipid droplets 
[264; 265]. There are a wide variety of functions that lipid droplets are proposed to do, 
but the standard view is that they are lipid storage organelles. It is unclear whether 
astrocytic lipid droplets might have a function beyond lipid storage, but the evidence 
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observed thus far supports this simple view of excess lipid storage. Astrocytes that do not 
accumulate lipid droplets after myelin internalization may have recycled the lipids for 
energy or membrane remodeling [266].  
Lipid droplets quantified in SBEM volumes of the MTZ of D2 (mild) showed an 
increase in lipid droplet formation before the laminar region, and there were equally high 
numbers of lipid droplets in the glial lamina and MTZ of D2 (severe). This suggests MTZ 
astrocytes respond to a stimulus prior to or faster than glial laminar astrocytes, or that the 
MTZ was the site for the stimulus inducing lipid droplet formation before the glial 
lamina. The lack of biological replicates prevents strong conclusions from being made 
from this particular dataset, but other results shown here suggest that the MTZ is a 
dynamic region with increased myelin irregularities and astrocytes that might be more 
sensitized for phagocytic activity.  As suggested by our ultrastructural and in vitro myelin 
feeding experiments, we propose that lipid droplet accumulation is due to repeated 
myelin internalization by astrocytes.  
Lipid droplets observed in myelin- and oleic acid-fed cultured astrocyte were 
primarily of 2 different forms, with the larger lipid droplet containing an electron-lucent 
core and the smaller lipid droplet being primarily electron-dense. The osmiophilic 
appearance may reflect the bulk incorporation of different myelin lipid species and the 
electron-lucent core may represent diffusion of lipids within the droplet [267; 268]. To 
test this hypothesis, cultured astrocytes should be collected at time points after lipid 
stimulation and examined by TEM. A fully matured lipid droplet should appear electron-
lucent using our method of EM processing.  
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Lipid droplet formation in astrocytes might be interpreted as a sign of pathology. 
If the astrocytes excessively phagocytose myelin, this may secondarily affect some of 
their other normal functions, similar to how lipofuscin accumulation affects RPE cells. A 
gradual disabling of phagocytic astrocytes through decreased myelin internalization and 
accumulation of myelin or lipid droplets could be a contributor to slowly progressing 
diseases like glaucoma. 
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Figures 
 
 
Figure 3.1. QD-9 reactivity and myelin loss in D2. A. Immunofluorescence labeling of 
QD-9 in ONH of D2 and D2-Gpnmb+. Region in white box magnified at right. Some 
small, highly immunofluorescent QD-9 objects appeared detached (arrow) from myelin 
sheaths and other QD-9 objects appeared to have a thin protrusion extending away from 
the myelin sheaths (arrowheads). B. MSV quantification of ONH labeled with QD-9. 
Shaded region contains SV where values in the two groups are different at a Student’s 
unpaired t-test with Welch’s correction significance level of p < 0.005. Vertical dotted 
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line is SV closest to mean fold-change within shaded region; error bars are SEM. C, D. 
Western blot and quantification from individual optic nerves for MBP and actin (MW = 
42 kDa) for as a loading control. Three isoforms of MBP (MW = 18, 17, 14 kDa) were 
cumulatively quantified from each nerve and normalized by mean signal in D2-Gpnmb+.  
Nerves were classified as non-degenerated (Lanes 1, 2, 3; blue), sectorial degeneration 
(Lane 5; red), or late degenerated (Lanes 6, 7, 8; white). Additional western blot of ONH 
not shown. p = 0.01 in two-tailed, unpaired t-test with Welch’s correction; error bars are 
SD. (Scale bars, A: 70µm left, 20µm right.)  
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Figure 3.2. Myelin irregularities in C57Bl/6J MTZ. A, B, C. SBEM of irregular 
myelin in a non-degenerated ONH. A. Debris contained concentric rings of electron 
density (arrowheads) similar to the period lines of compact myelin. B. An oblique cutting 
plane of a myelinated axon that was folded back onto itself (arrowhead). C. A series of Z-
sections of a myelin protrusion. Panel showing distance at 0µm highlighted a typical 
myelinated axon (yellow). Advancing through the Z plane revealed a myelin protrusion 
projecting away from the myelin sheath. D. A 3D reconstruction of the myelin protrusion 
in C (dark red, axr). Nearby myelin sheaths (green, axg and blue, axb) were also traced. 
Black box highlights region of myelin protrusions (enlarged images shown to the right) 
inside of an astrocyte process (yellow) that also associated with a blood vessel (bv). 
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Center and right images are rotated views of myelin protrusions with and without the 
overlay of the astrocyte process. A long protrusion was inside the astrocyte process 
(white arrow) and smaller protrusions were observed nearby on the same axon (black 
arrow). N = nucleus. (Scale bars, A, B, C: 2µm.)  
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Figure 3.3. Osmiophilic irregularities in SBEM from D2 and D2-Gpnmb+ ONH. A. 
Irregular structures from the glial lamina and MTZ containing granular debris or myelin 
bodies (arrows) and spherical structures putatively called lipid droplets (arrowheads). 
Gradient of electron density in a glial process in MTZ of a mildly diseased optic nerve 
(black arrow). B. Reduced field of view using minimum intensity projections of 
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subvolumes with white arrows and arrowheads pointing to same structures in A. C, D. 
Automated quantification of SBEM electron-dense spherical lipid droplets. C, Total 
number of lipid droplets counted from minimum intensity projections. The mildly 
diseased D2 showed a difference between the number of lipid droplets in the glial lamina 
and MTZ. D, Box-and whiskers-plot (5-95 percentiles) of lipid droplet volumes. 1-way 
ANOVA (p < 0.001) with Tukey’s comparison, pair-wise significance only considered 
between lamina and MTZ within each nerve, all laminas, or all MTZs (* = p < 0.05). 
Error bars are SD. (Scale bars, A, B: 5µm.)  
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Figure 3.4. Immunofluorescence of myelin internalization by cultured astrocytes. A. 
Antibody localization of MBP before (green) and after (red) membrane permeabilization 
(left). External MBP (arrows) and internalized MBP (arrowheads) were on top of or 
inside of, respectively, astrocytes labeled by GFAP (white). Myelin debris was visible by 
differential interference contrast (right). B, C, D. Quantification of immunofluorescence 
in cultured astrocytes after myelin feeding. Calculated Internal values and External values 
were normalized to the mean fluorescence in 1 hr or Day 1 fluorescence. Error bars show 
SEM. B. Myelin was fed to astrocytes for 1 hr before washout. MBP decreased after 
washout; 1-way ANOVA for Internal and External p < 0.001. C, D. MBP (C) and GalC 
(D) after myelin was fed continuously for 1 day before wash out. Internal MBP and GalC 
levels were unchanged after washout. 1-way ANOVA for Internal and External in C is p 
< 0.001. 1-way ANOVA for D, Internal is p < 0.001 and D, External is p = 0.002. Post-
hoc pair-wise Tukey analysis performed against Day 0 or as indicated, * = 0.01 < p < 
0.05; *** = p < 0.001. (Scale bar, A: 20µm.)  
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Figure 3.5. TEM of myelin debris and lipid droplets in cultured astrocytes. A. TEM 
of myelin- or oleic acid-fed astrocytes. Myelin debris was visible as large, irregularly 
shaped electron-dense structures (Day 1 myelin). Oleic acid incubation resulted in 
numerous large, spherical structures with an electron-lucent core (white arrowhead), 
smaller osmiophilic structures with irregular electron-density (white arrow), as well as a 
spherical structure that appeared to be an intermediate form of the two (black arrowhead). 
Repeated and continuous myelin feeding (Day 3 myelin) contained myelin debris and 
structures similar to those found after oleic acid incubation. N = nucleus. (Scale bars, A: 
20µm; D, left: 10 µm, right: 2 µm.)  
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Figure 3.6. ORO and Plin2 fluorescence increased after myelin or oleic acid feeding. 
A, B. Quantification of Oil Red O fluorescence (A) or Plin2 immunofluorescence (B) by 
microscopy after 3 days of repeated and continuous feeding. Error bars show SEM. Two-
tailed, unpaired t-test p < 0.001 between control and myelin-fed for ORO and Plin2. 
Images of ORO in lipid droplet core after oleic acid (OA) feeding (A, right) and Plin2 
surrounding lipid droplet membrane after myelin feeding (B, right). Shaded bars indicate 
samples with myelin added. (Scale bar, 10µm.)  
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Figure 3.7. Plin2 response after myelin feeding regimens. A. Continuous and repeated 
myelin feeding induced progressive Plin2 and MBP accumulation. Western blot of Plin2 
(MW = 47 kDa) and MBP (only 14 kDa band quantified, arrow) normalized against actin 
loading control showing errors bars with SD. 1-way ANOVA Plin2 p < 0.001; MBP p = 
0.02. B, C. Myelin fed for 24 hrs (B) or 1 hr (C) had no change in Plin2. B, 1-way 
ANOVA Plin2 p = 1.0; MBP p = 0.02. C, 1-way ANOVA Plin2 p = 0.98; MBP p = 0.02. 
Pair-wise comparisons using post-hoc Tukey test against Day 1-, 0 hr-, or as indicated, * 
= 0.01 < p < 0.05. Shaded bars indicate samples with myelin added.  
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Figure 3.8. Plin2 increased in mouse glaucoma models. A, B. Western blot of Plin2 
and Lgals3 (MW = 32 kDa) normalized to actin in same ONH from Figure 3.1C. D2 with 
axon loss all contained higher Plin2 and Lgals3 expression than D2-Gpnmb+ or D2 with 
NND. As before, Lanes 1, 2, 3 = non-degenerated, Lane 5 = sectorial degeneration, and 
Lanes 6, 7, 8 = late degeneration. Two-tailed unpaired t-test with Welch’s correction, 
Plin2 p = 0.001; Lgals3 p = 0.01, error bars with SD. C, D. MSV of Plin2 fluorescence 
increased in D2 (C) and translimbal laser photocoagulation model (D). Vertical dotted 
line indicates segmentation value closest to mean fold-change of SV under shaded region. 
D, shaded region contains p < 0.001, using unpaired t-test with Welch’s correction; error 
bars with SEM. E, shaded region contains p < 0.01, using unpaired t-test with Welch’s 
correction; error bars with SEM.  
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Figure 3.9. Plin2 localized to Lgals3+ astrocytes in D2 and D2-Gpnmb+ ONH. 
A. Immunofluorescence labeling of astrocytes (Lgals3, blue), microglia (Iba1, green), 
and lipid droplets (Plin2, red). Plin2 signal was predominantly localized to Lgals3-
expressing astrocytes and not Iba1-expressing microglia (arrowhead). B. Colocalization 
measured by Plin2 signal segmented within a mask layer of astrocytes (solid line) or 
microglia (dashed line). A neutral slope indicated no specificity of Plin2 within the 
microglia mask and a positive slope indicated co-localization of Plin2 within the 
astrocyte mask. (Scale bars, A: 70µm.) 
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Appendix A: The appearance of protease-resistant 
Sncg on lipid droplets in cultured cells and in 
axonal swellings Plin2Δ2-3 mouse ONH 
 
Preface 
Appendix B contains unpublished data regarding proteinase K-resistance of Sncg on lipid 
droplets and in optic nerves. 
Transmission electron microscopy of cells in Figure AppA7.1 was performed by Chung-
ha Davis.  
All other work was original data generated by JVN under the supervision of Nicholas 
Marsh-Armstrong. 
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Introduction 
Lipid droplets are ubiquitous organelles that contain a neutral lipid core, made up 
of primarily triacylglycerols (TAGs) and sterol esters enclosed within a single membrane 
consisting of mostly phospholipids. The neutral lipid composition can be diverse [269] 
and TAGs in storage may be metabolized for energy [270]. Lipids from lipid droplets 
have also been suggested to be used in cellular membrane remodeling [265; 266]. In the 
retina, lipid droplets formed by retinal pigment epithelial (RPE) cells are called retinyl 
ester storage particles, or retinosomes [263; 271].  This unique name reflects the storage 
of retinyl esters as opposed to TAGs or sterol esters. RPE cells must constantly supply 
photoreceptors with 11-cis-retinal, the chromophore used in light capture. After 
photoisomerization of the chromophore, the photoreceptor will shed its outer segments 
containing the chromophore. RPE cells phagocytose the shed material. The internalized 
chromophore is then esterified and stored in the retinosome. Subsequent isomerization 
and oxidation of the retinyl ester results in a regenerated 11-cis-retinal chromophore 
[263]. Retinosomes have been associated with Plin2 [262] and are distinct from 
lipofuscin [262; 263], which are autofluorescent, non-degradable lipids and proteins that 
aggregate in the RPE. Lipofuscin accumulation is associated with age-related macular 
degeneration [258; 260; 261]. The function of lipid droplets in RPE cells in recycling 11-
cis-retinal demonstrates that lipid droplets play an important role in the visual system. 
The lipid droplet membrane can associate with many different proteins but the 
main lipid droplet proteins come from the PAT family of genes [272; 273]. The PAT 
family was recognized through structural similarities and functional association with lipid 
droplets. The original members of the family include Plin1 (Perilipin-1), Plin2 (Adipose 
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differentiation-related protein/Adipophilin), and Plin3 (Tail interacting protein of 47 
kDa/Mannose-6-phosphate receptor binding protein 1) [273]. Plin4 (S3-12) and Plin5 
(Lipid storage droplet protein 5/Oxidative PAT) were subsequently added to the family.  
Perilipins are expressed at high levels in adipocytes and steroidogenic cells [247; 
274]. Cells in different tissues may express different combinations of PAT proteins and 
even lipid droplets within an individual cell can express a different assortment of PAT 
proteins [247; 270]. Plin2 and Plin3 may be of greater relevance to study lipid droplets in 
the central nervous system (CNS) because the expression of both genes are found in more 
cell types than other PAT proteins [247; 248]. However, Plin3 expression is stable in the 
cytosol without association with lipid droplets [275]. Plin3 may identify nascent lipid 
droplets [275] that serve other functions besides storing accumulated lipids. Plin2 is only 
stable when associated with lipid droplets [249]. The stabilization of Plin2 by lipid 
droplets may make it a better marker to identify putative lipid droplets in cells. 
Plin2 was first identified through an increase in mRNA expression during 
adipocyte differentiation of the 1246 cell line derived from C3H mouse teratoma [276]. 
Plin2 expression may have a role in the differentiation of adipocytes, but can also 
perform functions in other cell types [247]. Plin2 had a slight preference for TAG-rich 
lipid droplets in multiple cell lines [277] and is believed to have a role in preventing 
lipolytic activity, specifically by inhibiting the access of ATGL to TAGs [278; 279].  
There may be a novel role for Plin2 in regulating the localization of SNAP-23, a 
SNARE protein, to lipid droplets [280]. The overexpression of Plin2 in cultured cells 
segregated SNAP-23 away from glucose transporter vesicles and over to lipid droplets. 
This is an interesting concept because gamma synuclein (Sncg), a gene highly expressed 
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in retinal ganglion cells (RGCs), was also suggested to protect TAGs from ATGL-
mediated lipolysis and interact with SNAP-23 [281]. Knockdown of Sncg in 3T3-L1 
adipocytes increased the associate of ATGL with lipid droplets. Sncg was proposed to act 
as a chaperone for SNAP-23 by regulating its assembly with the SNARE complex that 
forms on the surface of lipid droplets. The formation of the SNARE complex is proposed 
to mediate lipid droplet fusion, which would be akin to synaptic vesicle fusion. Plin2 was 
also proposed to have a role in mediating milk lipid globule (MLG) secretion in 
mammary glands [282; 283]. Plin2 was found to be a constituent of MLGs and was 
proposed to act as an adaptor molecule that assists in the association of the MLG to the 
plasma membrane, butyrophilins, and/or xanthine oxidoreductase. Butyrophilins and 
xanthine oxidoreducatase are proteins involved in MLG secretion that is distinct from a 
classical secretory pathway that uses exocytosis [283; 284]. The intersection of lipid 
droplet biology and synaptic vesicle biogenesis may provide the insight needed to 
understand the role Sncg may have outside the CNS and the role Plin2 may have within 
the CNS.  
Lipid droplets were typically regarded as sites to store excess lipids, but 
increasing research suggests that the presence of neutral lipids and the lipid droplet 
membrane can have additional roles in cell biology [264; 265; 268; 285-287]. We found 
that Sncg localized to lipid droplets in 661W cells, a transformed mouse photoreceptor 
line that was thought to be a rat RGC line [288; 289]. At the time of the initial 
experiments described here, 661W were called RGC-5 cells and our confirmation of its 
mouse origin restricted our further use of the cells. The unexpected localization of Sncg 
to lipid droplets in 661W cells led us to discover lipid droplets in the optic nerve (Chapter 
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3). Here I report experiments performed to understand whether there was a relationship 
among Sncg, lipid droplets, and Plin2.  
 
 
Results 
Sncg localized to lipid droplets in 661W cells are PK-resistant 
Cultured 661W cells formed lipid droplets in culture media containing 10% fetal 
bovine serum that naturally contains a mixture of fatty acids and cholesterol. The addition 
of oleic acid increased the number and size of lipid droplets (personal observations). 
661W cells were cultured in media supplemented with 30µM oleic acid for 24 hours to 
increase lipid droplet formation. After fixation, lipid droplets were labeled with the 
fluorescent neutral lipid dye BODIPY (Figure AppA.1A) or an antibody against Plin2 
(Figure AppA.1B), and an antibody against the C-terminal domain of Sncg, Sncgaa108-123. 
BODIPY dye formed spherical structures in the cytoplasm and Sncg localized around the 
perimeter of BODIPY+ lipid droplets. Plin2 also labeled the perimeter of lipid droplets 
and colocalized with Sncg. Sncg appeared as small puncta decorating the surface of the 
lipid droplet, but had a smoother, more membranous appearance on larger lipid droplets. 
Plin2 typically appeared membranous, but not continuous, around the lipid droplet 
membrane. BODIPY and Plin2 are two common lipid droplet markers that labeled lipid 
droplets in 661W cells. Sncg was a third marker not previously associated with lipid 
droplets.  
Because alpha synuclein (Snca) displayed proteinase K (PK) -resistant qualities in 
certain types of pathology [184; 185] and Sncg shared structural similarities to Snca [290; 
291], we also examined whether Sncg was PK-resistant in cultured cells. The antibody 
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against Sncgaa21-127 was PK-sensitive and had diffuse, nuclear localization before PK 
treatment. After PK treatment, Sncgaa21-127 labeling was abolished. The diffuse, cytosolic 
population of Sncgaa108-123 labeling was reduced after PK treatment, but the Sncgaa108-123 
immunofluorescence that localized to lipid droplets remained robust after PK treatment. 
These experiments have shown that not only does Sncg associate with lipid droplets, but 
also that the C-terminus specifically associated with lipid droplets and was PK-resistant.  
PK-resistant Sncg structures in Plin2Δ2-3 optic nerves specifically reactive against 
Sncgaa108-123 antibody 
Sncg was also PK-resistance in diseased optic nerve [11]. We hypothesized that 
Sncg might be found on lipid droplets in the CNS. Sncg was unreliably detected on lipid 
droplets in the optic nerve head (ONH), although some Sncg+ astrocytes and Lgals3+ 
astrocytes contained ring-shaped structures that were labeled with two antibodies for 
Sncg and with Plin2 antibody (data not shown).  
The function of Plin2 may be redundant with other lipid droplet proteins. The 
knockdown of Plin2 expression in cultured cells resulted in other proteins and perilipins 
localizing to lipid droplets [247; 278], and Plin3 can functionally compensate for Plin2 
[292]. To determine whether Sncg would localize to lipid droplets in the ONH if Plin2 
were absent, the ONHs of Plin2-deficient mice (Plin2Δ2-3) were examined. The extensive 
labeling of Sncg in the optic nerve axons made it difficult to resolve whether Sncg 
formed structures that appeared to be lipid droplets (data not shown).  
Although it was unclear whether there was a lipid droplet-associated phenotype of 
Sncg, two Sncg antibodies labeled unusual structures that were ranged from ~15µm-
30µm along its long axis (Figure AppA.3A, top row). ONHs were then treated with PK 
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to determine whether the structures might be similar to pathological PK-resistant Snca 
structures. After treatment with PK, structures were only detected by Sncgaa108-123 
labeling (Figure AppA.3A, bottom row). These structures appeared in Plin2Δ2-3 ONH 
starting approximately at 6-7 months (mos) of age, and were typically larger and more 
numerous with increasing age. The Sncg structures may be indicative of an age-related 
disease.  
We attempted to determine whether Sncg structures formed as a result of optic 
neuropathy. A glaucoma model using acute intraocular pressure increase (IOP) via 
translimbal laser photocoagulation was performed on two cohorts of Plin2Δ2-3 mice and 
Balb/C mice, the background strain. One cohort included 3 to 5-mo-old mice (Balb/C N 
= 13; Plin2Δ2-3 N = 16) and a second cohort included 7-mo-old mice (Balb/C N = 14; 
Plin2Δ2-3 N = 10). Preliminary experiments indicated that Sncg structures did not form in 
young Plin2Δ2-3 mice with optic nerve degeneration after IOP elevation. Thus, the Sncg 
structures appeared to be related to age, and not degeneration. Plin2 deficiency also did 
not appear to affect susceptibility to axon degeneration because the number of optic 
nerves with degeneration was similar to the number with degeneration in the control 
strain. However, the majority of these mice did not have axon loss and so our sample size 
for estimating susceptibility was small.  
Sncg structures are intact, swollen axons 
It was then considered that the Sncg structure might be a large axonal swelling. 
The only known marker that was reactive with the structure was Sncgaa108-123. That 
antibody was unsuitable to use because Sncgaa108-123 labeled all axons in the optic nerve 
and it was difficult to trace a single axon to the Sncg structure. To properly localize Sncg 
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to the structure and also exclude the detection of endogenous mouse Sncg, a chimeric 
Sncg gene consisting of the first 1-110 amino acids (aa) of mouse Sncg was fused to the 
last 13 aa in the C-terminus of frog (Xenopus tropicalis) Sncg (xSncg). The retention of 
the mouse N-terminal sequence should prevent the disruption of lipid interactions by the 
protein. The frog C-terminal sequence can be selectively labeled using an antibody that 
does not cross react with mouse Sncg. A mini Singlet Oxygen Generator (miniSOG) tag 
[293] was also added to the C-terminal end of the chimeric Sncg gene. The transgene was 
packaged into an adeno-associated virus, serotype 2 (AAV2) and injected intravitreally. 
RCGs would be infected and express the transgene in the cell body and axons.  
Cultured cells infected with the virus confirmed transgene expression and verified 
the specificity of the xSncg antibody (Figure AppA.4A). Transgene expression was 
examined in vivo by injecting the virus into the eye of a Balb/C mouse. After 3 days of 
infection, few RGCs were labeled with xSncg antibody and miniSOG fluorescence 
(Figure AppA.4B). 
AAV2-mSncgX-miniSOG was unilaterally infected into the eyes of 10 to 12-mo-
old Balb/C and Plin2Δ2-3 mice. Tissue was harvested after 1 mo. PK treatment was 
applied to ONHs in order to reduce background labeling and enhance the reactivity of the 
transgene to the antibodies. The antibody against Sncgaa108-123 labeled all axons in the 
nerve, as expected (Figure AppA.5A). A fraction of axons were labeled using antibodies 
against xSncg (Figure AppA.5B) or miniSOG (Figure AppA.5C). In Plin2Δ2-3 ONH, 
Sncg structures were present and some structures appeared to be continuous with axons. 
It was inferred that all labeled structures were still connected to the proximal axon within 
the one month of infectivity because it was labeled by the transgene. The conclusion was 
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that the Sncg structures were axon swellings that were likely forming in degenerating 
axons. 
We previously observed that axon swellings may eventually be phagocytosed by 
astrocytes [11]. ONHs of 12-mo-old Plin2Δ2-3 were labeled with Lgals3 to determine 
whether there would be Lgals3 reactivity surrounding the axon swelling. Lgals3 did not 
appear to have any particular reactivity with the Sncg structure (personal observations). 
Swollen axons contain vesicular and granular material 
Imaging by confocal microscopy showed that an axon swelling had irregular 
morphology (Figure AppA.6A). One swelling initially appeared balloon-like, and then it 
gradually elongated into a tubular structure (Figure AppA.6B). Individual Z-stacks 
resolved additional morphological detail inside the axon swellings. There was diffuse 
labeling in the axoplasm and also some spherical structure made up of puncta, which was 
reminiscent of Sncg decorating the membrane of lipid droplets.  
Transmission electron microscopy (TEM) was used to examine the ultrastructure 
of the swellings and also determine the identity of the structures within the swellings. 
Axon swellings were frequently myelinated and interspersed among other myelinated 
axons that were typical in appearance (Figure AppA.7A). Myelin sheaths appeared 
compact with period lines with no indications of abnormal myelin. The amount of 
material inside each swelling did not appear to determine the area of the swelling. Some 
swollen axons contained a relatively low density of granular and vesicular material, while 
other swollen axons had a high density of materials (Figure AppA.7B). Some of the 
structures were identifiable as mitochondria.  
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Confocal imaging suggested that Sncg formed ring-like structures within the 
swelling. We previously observed Sncg on the periphery of lipid droplets, but none of the 
vesicles within the swellings had an appearance consistent with a lipid droplet. It is 
unclear which of the vesicles might contain Sncg.  
One of the axon swellings identified did not appear myelinated (Figure 
AppA.7B). Instead, it was enclosed on one side with a thin membrane. On the opposite 
side of the swelling, a membrane was not apparent and the granular contents appeared 
open to the glial cytoplasm. There were no other obvious signs of gliosis or degeneration 
in these nerves. The axon swellings were observed in aged transgenic mice with a Plin2 
deficiency, in the absence of degeneration, by fluorescence imaging and TEM. 
 
Discussion 
I have reported here that Sncg localized to lipid droplets in the immortalized 
661W cone photoreceptor cell line. There are conserved structural characteristics among 
the synuclein family that indicates that the N-terminal domain binds lipids while the C-
terminal domain has relatively unrestricted movement [290; 291; 294-296]. Snca 
interacted with synthetic lipid vesicles in vitro, as well as to lipid droplets in Hela cells 
and primary hippocampal neurons [297]. Sncb also localized to lipid droplets in 
immortalized Hela cells. Sncg did not localize to lipid droplets in Hela cells [297] or 
adipocytes differentiated from mouse embryonic fibroblasts [281]. Therefore, the 
interaction of Sncg with lipid droplets appears context and cell-dependent. The 
characterization of the biology in which this interaction occurs may be informative of the 
function of Sncg.  
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There were two populations of Sncg that was labeled by antibodies directed 
against the N- or C- Sncg domains. It is unclear why the antibodies label distinct 
populations of Sncg. Sncg may have additional roles in gene regulation, in addition to 
cytoplasmic functions that regulate synaptic vesicles or lipid droplets.  
We were interested in the possibility that Sncg may be sequestered on lipid 
droplets. Lipid droplets might serve as a binding domain that prevents Sncg from 
interacting with its target protein or membrane [264; 265; 287]. It may be one mechanism 
by which the cytoplasmic concentration of Sncg may be regulated. The morphology of 
the Sncg puncta around lipid droplets suggested discrete domains that bound Sncg. It also 
appeared that larger lipid droplets had more continuous labeling of Sncg. We did not 
perform any experiments that might address whether Sncg influenced the size of the lipid 
droplet by protecting the TAGs from lipolysis or whether the lipid droplet recruited Sncg 
to its surface. There did not appear to be any effects on cell viability when cells were fed 
with oleic acid to increase lipid droplet formation (personal observations). Sncg did not 
seem to have a pathogenic effect on 661W cells, but perhaps any effect of Sncg 
overexpression was neutralized by lipid droplet binding.  
Axon swellings in Plin2Δ2-3 were a dramatic phenotype that occurred with age. 
Axon swellings were primarily found in the myelinated portion of the optic nerve. The 
number of swellings in each nerve varied, but was generally limited to less than 10 for 
any given nerve examined. Axonal debris was removed from axons via similar swellings 
and protrusions in a C57Bl/6J mouse [11], but the protrusions in these control mice were 
not observed to be as large as those in aged Plin2Δ2-3 mice. It is unclear why a Plin2 
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deficiency would cause this phenotype or whether the defect was due to a defect in the 
axon or glia.  
I was unable to identify reagents to assess whether there was an impact on lipid 
droplet formation in Plin2Δ2-3 optic nerve. Antibodies against Plin1, Plin2, Plin3, Plin5 
were all tested in optic nerve tissue. Plin2 was the only antibody that had reproducible 
and detectable reactivity, and that was only in degenerated optic nerve tissue (Chapter 3). 
Other PAT proteins may not be expressed in the ONH or have even lower endogenous 
expression than Plin2. It is also possible that the other perilipin antibodies tested were not 
compatible with the protocols used for preparing and immunolabeling of frozen optic 
nerve sections. The lipid dyes BODIPY, Oil red O, and Nile Red were also ineffective at 
labeling lipid droplets in the ONH, perhaps due to the abundance of myelin. Those dyes 
clearly labeled lipid droplets in liver tissue. Oil red O may have labeled lipid droplets in 
the optic nerve but the labeling was not clear enough for quantitative purposes. Due to 
these limitations, I was not able to examine whether lipid droplet formation could be 
affected in Plin2Δ2-3 mice. By TEM, Plin2Δ2-3 mice (N = 2) did not show lipid droplet 
accumulation in astrocytes that was observed in degenerated DBA/2J optic nerve 
(Chapter 3). It is unclear whether the axonal dystrophies in Plin2Δ2-3 mice were related to 
lipid droplet biology. 
Plin2, and lipid droplet proteins in general, are not frequently observed or studied 
in the CNS. The Plin2Δ2-3 mouse was shown to have a delayed dark adaptation response 
that affected photoreceptors and RPE cells [298]. RPEs also had reduced retinyl ester 
accumulation. This phenotype, and the swollen axons described here, may be the only 
described neurological phenotypes for Plin2Δ2-3 mice. These experiments have generated 
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more questions and provided little answers to the function of Sncg and the role of Plin2 in 
the CNS. It has suggested a possible effect of Plin2 expression in the CNS. It remains to 
be seen whether Sncg has a function in mediating lipid droplet fusion or vesicle 
formation in the optic nerve and whether Plin2 has a role in independent of lipid droplet 
association.  
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Figures 
 
 
Figure AppA.1. Sncg localized to lipid droplets in 661W cells. A. Sncgaa108-123 
antibody (red) labeled phase-dense (inverted image) and Bodipy-positive (green) lipid 
droplets. Sncg appeared punctate on the surface of lipid droplets. B. Sncg (red) 
colocalized with Plin2 (green) on lipid droplets. Larger lipid droplets had smoother Sncg 
labeling than the smaller lipid droplets in A. (Scale bar: A, B: 70µm.) 
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Figure AppA.2. Epitope reactive against Sncgaa108-123 antibody is PK-resistant and 
lipid droplet-specific in 661W cells. A. Cells labeled with antibodies against different 
regions of Sncg. Sncgaa21-127 (green) localized to the nucleus and had diffuse cytosolic 
labeling. After treatment with PK, Sncgaa21-127 labeling was abolished. Sncgaa108-123 (red) 
had diffuse cytosolic labeling and labeled lipid droplets. Diffuse cytosolic labeling was 
less apparent after PK treatment, but lipid droplet-associated labeling remained strong. 
(Scale bar: 70µm.)  
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Figure AppA.3. PK-resistant Sncg structures in 12-mo-old Plin2Δ2-3 ONH. A. Both 
Sncg antibodies labeled axons in the ONH. In aged Plin2Δ2-3 ONH after PK treatment, 
Sncg structures were selectively detected by Sncgaa108-123 (red). (Scale bar: 70µm.)  
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Figure AppA.4. Viral expression of mSncgx-miniSOG in 293 cells and mouse retina. 
A. Intrinsic fluorescence of miniSOG (green) colocalized with antibody directed against 
C-terminus of xSncg (red) in infected cells. B. Intravitreal injection of virus into 3-mo-
old Balb/C. Expression of miniSOG (green) and xSncg (red) in RGCs (brackets) 3 days 
post injection. Labeling of miniSOG outside the RGC layer was most likely 
autofluorescence. (Scale bars: A, B: 70µm.)   
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Figure AppA.5. Sncg structures in the optic nerve are axon swellings. A, B, C. PK-
treated optic nerve from Balb/C or Plin2Δ2-3. A. Sncgaa108-123 labeled axons in the optic 
nerve. B, C. Viral expression labeled by antibodies against xSncg (B) or miniSOG (C). 
Structures were labeled in Plin2Δ2-3 mice (white arrowheads), demonstrating that Sncg 
structures were axons continuous with RGCs at the time of infection. Insets, merged 
color files of uninfected optic nerves labeled with Sncgaa108-123 (A), xSncg (B), or 
miniSOG (C) (all in red); PK-sensitive Sncgaa21-127 (green); and DAPI (blue). (Scale bars: 
A, B, C: 70µm.)  
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Figure AppA.6. Sncg has granular appearance within axon swellings. A. Two axon 
swellings from same optic nerve labeled with endogenous Sncg (Sncgaa108-123). Sncg 
appeared punctate throughout the cytoplasm. B. AAV-mSncgx-miniSOG infected axons 
and axon swelling labeled with an antibody against the xSncg epitope. Punctate, round, 
and ovoid-shaped structures were in the cytoplasm. Numbers refer to position in microns 
of Z-stack. (Scale bars: A: 5µm; B: 7µm, C: 20µm.)  
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Figure AppA.7. Granular and vesicular materials in axon swellings seen by TEM. 
A, B. Osmiophilic myelin sheaths had regular periodicity around axons. Most axon 
swellings were myelinated, and contained low (A) and high (B) densities of granular 
material and organelles. B. Region of ONH closer to MTZ. A swelling with a high 
density of material (thick black border) had a thin membrane (black arrowheads) along 
one side of swelling. There did not appear to be a membrane separating the axon from the 
adjacent astrocyte on the other side of the swelling (asterisk). A myelinated axon was 
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oriented in an orthogonal direction to the remaining axons (thin black box). This axon 
was not as swollen as other axons, but contents of axoplasm were suggestive of an axon 
swelling. Arrow points to a thin myelinated axon protrusion with a round, myelinated 
figure at the tip. White arrowheads = mitochondria; N = nucleus; bv = blood vessel. 
(Scale bars: A, B: 2µm)  
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Experimental Materials and Methods 
 
Portions of this methods section were taken verbatim from the previously published 
methods section in Nguyen et al., 2011 [11].  
 
Animals. C57Bl/6J, Balb/C, DBA/2J (D2), and DBA/2J-Gpnmb+/Sj (D2-Gpnmb+) [30] 
(Jackson Laboratory); CD-1 (Charles River); C57Bl/6J Sncg-/- from V.L. 
Buchman, [176]; C57Bl/6J-Sncg+/- were bred from C57Bl/6J Sncg-/-; GLT-1-
eGFP from J.D. Rothstein [299]; Balb/C-Plin2Δ2-3 from K. Palczewski [298]. 
Mice were bred and maintained at the Johns Hopkins University Research Animal 
Resources facility on a 14hr/10hr light/dark cycle and fed ad libitum. Experiments 
used a combination of male and female mice, age-matched and sex-matched to 
control strains excluding SBEM studies. In SBEM studies, D2 mice were female 
and D2-Gpnmb+ was male. All experiments were in accordance with the 
Association for Research in Vision and Ophthalmology statement for use of 
animals in research with protocols approved by the Institute for Animal Care and 
Use Committee at the Johns Hopkins University School of Medicine. 
Translimbal laser photocoagulation. IOP was elevated unilaterally [45; 49] in 5- to 9-
mo-old C57Bl/6J Sncg−/− and Sncg+/− mice in groups matched for sex and age (7.6 
and 7.5 mos, respectively) and in 3- to 7-mo-old Balb/C and AdrpΔ2-3 mice in 
groups matched for sex and age. Burns were delivered directly behind the 
perilimbal plexus vessels and along the episcleral veins all around the limbus. IOP 
was measured with a rebound tonometer (TonoLab; Colonial Medical Supply). 
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Only mice with peak pressures greater than 25mm Hg were included in the study 
of Sncg−/− and Sncg+/− mice.  
Optic nerve crush. Intraorbital crush to the optic nerve were delivered approximately 2 
mm posterior to the globe for approximately 2 seconds using curved cross-action 
forceps (no. 7; Dumont), essentially as described [300]. 
Tissue preparation.  Mice were asphyxiated with CO2, transcardially perfused with 
phosphate-buffered saline, pH 7.4 (PBS), followed by 4% paraformaldehyde 
(PFA). Ocular tissues were fixed overnight in 4% PFA. Wholemount retinas were 
stored in 100% methanol. Optic nerves were saturated overnight with 30% 
sucrose in PBS, then set into blocks using Optimal Cutting Temperature (Tissue-
Tek), and frozen.  
In situ hybridization. Wholemount retinas were processed for in situ hybridization using 
digoxigenin-labeled riboprobes for Sncg transcribed from cDNA (IMAGE clone 
1448798; OpenBiosystems). Probes were hydrolyzed and detected using Cy3 
tyramides (Perkin-Elmer), as previously described [10].  
Immunochemistry. Antibodies used were Sncgaa108-123 (Covance); Sncgaa21-127 
(Genetex); GFAP (Sigma-Aldrich, Dako, and Synaptic Systems); QD-9 and β-
actin (Abcam); pNF (SMI31, Covance); Plin2 (Progen Biotechnik); MBP, GalC, 
cathepsin D (Millipore); Lgals3 (ATCC); Iba1 (Wako); LAMP1 and LAMP2 
(Developmental Studies Hybridoma Bank); cathepsin K (Santa Cruz 
Biotechnology, Inc.); catalase (Binding Site); PMP70 and Pex14 (from Stephen 
Gould, Johns Hopkins University School of Medicine, Baltimore, MD via Paul 
112 
 
Watkins, Hugo W. Moser Research Institute at Kennedy Krieger, Baltimore, 
MD).  
Secondary antibodies used were anti- mouse AlexaFluor 488, mouse Cy3, rabbit 
AlexaFluor 488, rat Cy5, rat AlexaFluor 488, and guinea pig AlexaFluor 488 
(Invitrogen); anti- mouse Cy5, rabbit Cy3, rabbit Cy5, rat Cy3, guinea pig Cy3, 
and guinea pig Cy5 (Jackson ImmunoResearch Laboratories). 
The standard labeling protocol of cells or tissue was permeabilization with 0.1% Triton-X 
100 in PBS (PBS-T) for 10min, blocked with 10% normal goat serum (NGS) 
diluted in PBT for a minimum of 30min, incubation with primary antibody diluted 
in 5% NGS/PBT for 1hr to overnight, washed 3 times with PBT for a minimum of 
5min each, incubation with secondary antibody in 5% NGS/PBT for 45min, 
washed 3 times with PBT for a minimum of 5min each, counterstained with DAPI 
diluted in PBS for 10min, washed 3 times with PBS for a minimum of 5min each, 
then mounted using Aqua-Poly/Mount (PolySciences, Inc.). 
PK-resistant Sncg was detected by treating sections or cells with 25 μg/mL PK for 5 min 
before incubation with the primary antibody. Nuclei were detected by 4',6-
diamidino-2-phenylindole (DAPI) in Tris-EDTA, pH 8 used at 20μg/μL. 
Lipid dyes. ORO was prepared as 1% solution dissolved in propylene glycol using a 
protocol modified from a previous study [246]. Cells were washed with 100% 
propylene glycol, incubated with 1% ORO for 1 hr, then washed with 85% and 
50% propylene glycol for 2 min each. ORO and Plin2 labeled samples were 
mounted in 90% glycerol containing 100mM Tris, pH8.7 and 1mg/mL p-
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phenylenediamine. BODIPY 493/503 (Molecular Probes) was prepared in PBS 
and used at 0.1mg/mL for 10 min.  
Cell culture. 661W cells were obtained from N. Agarwal (University of North Texas 
Health Science Center, Fort Worth, TX). Sequencing of the Thy1 gene confirmed 
that they were of mouse origin, as reported [288; 289]. Cells were cultured in high 
glucose Dulbecco’s Modified Eagle Medium (DMEM-HG) containing 10% fetal 
bovine serum, 100U/mL penicillin and 100ug/mL streptomycin, and 2mM 
glutamine.  
Cells were transfected with GFP fusion constructs containing the full-length mouse Sncg 
(pCS2-GFP-Sncg) or mouse Sncg lacking the last 15 aa in the C-terminus (pCS2-
GFP-SncgΔC) using Lipofectamine 2000 (Invitrogen) and fixed with 4% 
paraformaldehyde (PFA) before immunostaining.  
Primary astrocytes were cultured using a protocol modified from a published protocol 
[301], with guidance from L. Foo and B. Barres (personal communication). 
Cerebral cortices from neonatal p0-p3 CD-1 and Balb/C mice were dissociated 
using papain and 625U DNase (both Worthington Biochemicals), washed and 
triturated using a solution containing 1.5mg/mL ovomucoid trypsin inhibitor 
(Worthington Biochemicals), 1.5mg/mL bovine serum albumin (Sigma-Aldrich), 
and 1250U DNase (Ovo-BSA). After pelleting, cells were resuspended in 2X 
Ovo-BSA with 437U DNase and centrifuged again. Cells were passed through 
40µm cell strainer and plated at approximately 260,000 cells/cm2 on poly-L-
lysine-coated flasks in DMEM-HG containing 10% fetal bovine serum, 100U/mL 
pencillin and 100µg/mL streptomycin, 2mM glutamine, 5µg/mL insulin, 10µM 
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hydrocortisone, and 5µg/mL N-acetyl-L-cysteine (ACM). After cells reached 
confluency, they were washed with Dulbecco’s PBS (D-PBS) and shaken 
vigorously by hand to remove overlying oligodendrocytes. Cells were allowed to 
recover for two days before adding 10µM Cytosine β-D-arabinofuranoside (AraC) 
to remove microglia. Cells were fed regularly with ACM + AraC until visual 
homogeneity. Purity was assessed by estimating the percent of GFAP+ (≥ 75%) 
and Iba1+ (≤ 1%) cells. 
Myelin and oleic acid feeding. Myelin was prepared from frozen bovine optic nerves 
with procedures modified from a previous protocol [302]. Nerves were de-
sheathed and minced before homogenization in 8 volumes of 0.33M sucrose on 
ice. Homogenates were layered over cold 0.66M sucrose, and myelin was 
recovered at the sucrose interface after 1 hr at 68,400 x g. After dilution with 1 
volume distilled water and repeat ultracentrifugation, myelin was washed three 
times by dilution with 2.6 volumes distilled water and pelleted at 68,400 x g 
before it was finally resuspended at 2-5mg/mL in distilled water, aliquoted, and 
stored at -20°C.  
For astrocyte feeding experiments, cells were seeded at 20,000 cells per Matrigel-coated 
(1:500 dilution in D-PBS) 8mm glass coverslips placed in a 48-well plate. After a 
minimum of 30hrs in culture, 3µg of myelin diluted in 20mM HEPES-
supplemented ACM (ACM-HEPES) was added to each well and the plate was 
centrifuged at 500 x g for 3 min. Bovine serum albumin-conjugated oleic acid 
(Sigma-Aldrich) was used at varying concentrations diluted in ACM-HEPES.  
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To differentiate myelin on the surface of cells from myelin that was internalized, myelin 
antibodies were used before and after membrane permeabilization using a 0.5% 
Triton-X 100 for 10min. For quantification, the area of the signal obtained from 
myelin debris outside of cell membranes was subtracted from post-permeabilized 
myelin signal. The remaining signal intensity was quantified (referred to as 
Internal myelin). 
To prepare samples for western blot, 200,000 cells were seeded onto Matrigel-coated 6-
well plates or 35mm dishes. Thirty micrograms of myelin was added to each well 
and centrifuged at 500 x g for 5 min. At the appropriate time point, astrocytes 
were washed 3-5 times with D-PBS and then fixed with 4% PFA or lysed with 
RIPA buffer supplemented with EDTA-free protease inhibitor cocktail (Roche) 
(RIPA+PI), depending on experiment; otherwise cells were re-incubated with 
HEPES-ACM.  
Image acquisition and analysis. Immunofluorescence, phase, and differential 
interference contrast images were acquired using Zeiss 200 M inverted 
fluorescent microscope and CoolSnap camera. IPlab imaging software (Becton 
Dickinson) was used for acquisitions and analyses. 
Optic nerve tissue. Multiple sections were quantified for each optic nerve. Instead of 
selecting one segmentation (threshold) level for quantifications, fifty fluorescent 
measures were obtained, as previously done [303]. The fluorescence at each 
segment was averaged for each optic nerve. The mean fluorescence of optic 
nerves were then averaged for each genotype or experimental condition. A two-
tailed, Student’s t-test was calculated between 2 groups across SV. The SV that 
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met a particular statistical significance level was then analyzed to determine fold-
changes between the groups. The mean of the fold-changes was identified and 
reported. Analysis of data performed using Excel (Microsoft) and GraphPad 
Prism (GraphPad Software). 
To measure fluorescence of a marker (Lgals3 or Plin2) within a particular cell type 
(GFAP- or Lgals3-expressing astrocytes or Iba1-expressing microglia), an image 
mask was created from the astrocyte or microglia image according to SV. The 
segmented fluorescence of Lgals3 or Plin2 was measured within each new image 
mask made from increasing SV of the astrocyte or microglia. 
Cultured astrocytes. Data collected from all astrocyte immunofluorescence experiments 
were obtained by imaging 9 fields of view from each of quadruplicate samples. 
Each field was individually curated for autofluorescence and other artifacts, with 
a minimum of 3 images used to quantify each experimental condition. Each 
experiment was performed in triplicate and the data presented are the means of 
those replicates. 
A 5µm (in cultured astrocytes) or 10µm (for optic nerves) rolling-ball background 
subtraction (IPlab) was used to enhance lipid droplet images before automated 
quantification.   
Western blotting. Lysates were briefly sonicated before protein quantification using 
Pierce 660nm Protein Assay (Thermo-Scientific). Fifty micrograms of protein 
were denatured using sodium dodecyl sulfate (SDS) sample buffer (50mM Tris-
HCl, pH6.8, 2% SDS, 10% glycerol, 100mM β-mercaptoethanol, 0.1% 
bromophenol blue) and heat before loading onto precast 4-15% polyacrylamide 
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Mini Protean TGX Tris-glycine gels (Bio-Rad). Electrophoresis was performed at 
75-100V in Towbin buffer (25mM Tris, 192mM glycine) with 0.1% SDS. 
Proteins were transferred onto nitrocellulose membranes (0.45µm pore, 
Whatman)  at 100V for 1 hr in Towbin buffer with 10% methanol, then incubated 
for a minimum of 30min in Odyssey blocking buffer (LI-COR), primary 
antibodies overnight in Tris-buffered saline containing 0.1% Tween-20 (TBT), 
then infrared secondary antibodies (anti-guinea pig IRDye800CW, anti-rabbit 
IRDye800CW (LI-COR); anti-mouse AlexaFluor 680 (Invitrogen); anti-rat 
DyLight 800 (Thermo-Fisher)) in TBT for 1hr after washes in TBT. Membranes 
were imaged using a Licor scanner. Membranes were reprobed for additional 
secondary antibodies, or stripped using 0.1M glycine, pH 2 or OneMinute Plus 
Western Blot stripping buffer (GM Biosciences) before additional labeling with 
primary and secondary antibodies. Protein bands quantified using ImageJ by 
selecting each lane using the Rectangular tool and plotting the selection [304]. 
The area under the relevant peak was selected by drawing a straight line from 
valley to valley flanking the peak and then quantified. All experiments were 
performed in triplicate. Normalization performed with actin. Protein-to-actin ratio 
reported for cell culture experiments. The mean protein-to-actin ratio of D2-
Gpnmb+ ONH was calculated and each protein-to-actin ratio was then normalized 
to that mean. 
MTT assay. Astrocytes were plated in a 96-well plate at 5000 cells/well. Myelin was 
added as described above. After 24 hrs, myelin was washed out and cells 
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incubated for 4 days. MTT was added to cells for 1 hr. Acidified 20% SDS was 
added and left overnight to solubilize MTT. Absorbance was read at 570nm.  
Electron microscopy. Serial block-face scanning electron microscopy. SBEM employs a 
microtome inside of a scanning EM as originally described by Leighton [305] and 
refined by Denk and Horstmann [306]. Optic nerves from 9-mo-old D2 were pre-
screened for axonal degeneration using distal cross-sections labeled with Sncg 
and/or pNF to enable us to sample different disease stages. These mice, along 
with 9-mo-old D2-Gpnmb+ and C57Bl/6J optic nerves were anesthetized with 
pentobarbital and transcardially perfused with Ringer solution followed by 2.5% 
glutaraldehyde/2% PFA in cacodylate buffer (Ted Pella) containing 2 mM CaCl2 
(CAC+Ca buffer). An eye was removed and the ONH carefully dissected and 
postfixed in the same fixative agent for 2 hrs at 4°C. The nerve was washed in 
CAC+Ca buffer for 30 min at 4°C. The nerve was placed in CAC+Ca buffer 
containing 2% OsO4 and 1.5% potassium ferrocyanide for 3 hrs at room 
temperature (RT). The nerve was washed with ddH2O 3 times for 5 min and then 
placed in 1% aqueous thiocarbohydrazide (Sigma-Aldrich) for 20 min at RT. The 
nerve was washed 3 times for 5 min in ddH2O and then placed in 2% aqueous 
OsO4 for 1 hr at RT. The nerve was washed three times for 5 min and placed in 
1% aqueous uranyl acetate at 4 °C overnight. The nerve was washed three times 
for 5 min in ddH2O and incubated in lead aspartate solution in a 60°C oven for 30 
min, as described previously [307]. The nerve was washed 3 times for 5 min in 
ddH2O and then dehydrated in a series of ice-cold ethanol solutions (20%, 50%, 
70%, 90%, 100%, 100%) followed by ice-cold anhydrous acetone for 10 min. The 
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nerve was placed in acetone at RT for 10 min and then infiltrated with an 
ascending series of Durcupan:acetone solutions. The nerve was infiltrated with 
100% Durcupan and then cured at 60°C for 2 days. The nerve was trimmed to 
remove excess plastic and attached to an aluminum pin, grounded with silver 
paint, and sputter coated with gold–palladium before imaging. 
Specimens were imaged on a Quanta SEM (FEI) equipped with a 3View serial block-face 
system (Gatan). Specimens imaged at high vacuum with 2.5-kV beam current and 
70-nm sectioning thickness. A 2D montage was collected at each Z plane to 
increase field of view. Volumes were stitched and analyzed by using IMOD 
(http://bio3d.colorado.edu/imod/) [308]. 
Estimates of spherical electron-dense structures (i.e., lipid droplets) within astrocytes 
were obtained using Imaris (BitPlane).  For this, 25.4mm3 subvolumes were 
extracted from larger volumes using IMOD and then imported into Imaris 
software for thresholding-based identification and quantification. Images were 
inverted and the Surfaces tool was applied to select objects. After local 
background subtraction of 500nm, object filters for intensity (within 75% of 
maximum), voxel size (excluding objects smaller than 30nm diameter), and 
sphericity (excluding sphericity lower than 0.75) thresholds were set. These 
parameters were selected based on a smaller subvolume in the D2 (mild) MTZ 
and then applied uniformly to all other samples. The creation of a mask made 
from the Surfaces objects allowed manual review of the data which showed that 
D2 nerves were undercounted more severely than D2-Gpnmb+ due to many 
objects being in close proximity to each other.  
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Transmission electron microscopy. Astrocytes that were fed myelin were analyzed by 
TEM with procedures modified from a previous study [309].  Astrocytes were 
fixed for 1 hr in 2.5% glutaraldehyde/2% PFA in 0.1M sodium cacodylate buffer, 
pH 7.4 (all from Electron Microscopy Sciences) with 2mM calcium chloride 
(Sigma-Aldrich) on ice. Cells were post-fixed with ferrocyanide-reduced osmium 
tetroxide (1.5% potassium ferrocyanide (Sigma-Aldrich)/2% osmium tetroxide 
(Electron Microscopy Sciences) in H2O), stained with 1% thiocarbohydrazide 
(Polysciences, Inc.) followed by 2% osmium tetroxide. Cells were subsequently 
stained with 1% uranyl acetate (Electron Microscopy Sciences) before 
progressive dehydration into ethanol. Durcupan-embedded cells were hardened 
for 36-48 hrs at 60-65°C. 60nm-thick sections were imaged using H7600 
transmission electron microscope (Hitachi).  
Generation of and infection with AAV2-mSncgXt-mS. Chimera of mouse aa 1-110 
and Xenopus tropicalis aa 117-130 with a C-terminal miniSOG tag was cloned 
into a AAV2.CB7. CI vector. Virus was generated by University of Pennsylvania 
Vector Core. Mice were anesthetized with Avertin and unilaterally injected 
intravitreally with 2μL of 1.78 x 1012 genome copies/mL per eye.  
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